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Regulatory Mechanism of Myeloid Derived Suppressor Cell Activity
Cesar Alexander Corzo
ABSTRACT

Myeloid-derived suppressor cells (MDSC) are a major component of the immune
suppressive network that develops during cancer. MDSC down-regulate immune
surveillance and antitumor immunity and facilitate tumor growth. The ability of MDSC
to suppress T cell responses has been documented; however the mechanisms regulating
this suppression remain to be understood. This work proposes a biological dichotomy of
MDSC regulated by the tumor microenvironment. In peripheral lymphoid organs MDSC
cause T-cell non-responsiveness that is antigen-specific. These MDSC have increased
expression of NOX2, enabling them to produce large amounts of reactive oxygen species.
Since the transcription factor STAT3 is substantially activated in MDSC, its potential
role in upregulation of NOX2 expression was investigated. Over-expression of a
constitutively active form of STAT3 increases expression of NOX2 subunits, whereas
attenuation of STAT3 activity leads to decreased expression of NOX2. The significance
of NOX2 in ROS generation is demonstrated in mice devoid of NOX2 function; NOX2deficient MDSC are unable to inhibit antigen-induced activation of T cells. In contrast,
MDSC within the tumor microenvironment have a diminished potential to generate ROS
but acquire expression of arginase and inducible nitric oxide synthase, enzymes
v

implicated in T cell non-responsiveness. Upregulation of these enzymes results in MDSC
ability to inhibit lymphocyte response in absence of antigen presentation. The tumor
microenvironment also promotes the differentiation of MDSC to tumor associated
macrophages.
Hypoxia is an exclusive feature to the tumor microenvironment and we
investigated its involvement in the properties of MDSC at the tumor site. Exposure of
spleen MDSC to hypoxia converts MDSC to non-specific suppressors and induces a
preferential differentiation to macrophages. Stabilization of HIF-1!, a transcription factor
activated by hypoxia, induces similar changes in MDCS as hypoxic exposure. Finally,
ablation of HIF-1! prevents MDSC from acquiring factors that enable the suppression of
T cells in absence of antigen. These findings help to expand our understanding of the
biology of MDSC and suggest a regulatory pathway of myeloid cell function exclusive to
the tumor microenvironment. They may also open new opportunities for therapeutic
regulation as we now should take into consideration how systemic location affects the
function of MDSC.

vi

INTRODUCTION

Cancer and the Immune System
Cancer is among the most life-threatening diseases and has risen to become the
second leading cause of death in the developed world. Most cancer patients are treated by
a combination of surgery, radiation, and/or chemotherapy. While these standard therapies
are efficient at treating the primary tumor, cancer still causes 25% of mortalities in the
industrialized world. The primary reason for the failure in mortality prevention is the
ineffectiveness of traditional treatments in controlling metastatic spread of the disease.
Deficiencies in immune responses have been extensively described in cancer
patients. The observation that tumor-infiltrating lymphocytes (TILs) and antigen
presenting cells (APCs) are non-functional in tumor tissues exemplifies the defects in the
immune system (1-5). Decreased numbers of mature dendritic cells (DCs) have been
observed in the lymph nodes and spleen of tumor-bearing mice (1,2,3), and in peripheral
blood of cancer patients (4). In addition to the DC defects, T cells are rendered tolerant to
tumor antigens early during tumor progression (5) demonstrating that the T lymphocyte
compartment also becomes systemically impaired.
The failure of the immune system to eradicate tumor cells is arguably due to its
inability to recognize cancer cells in an immunogenic context. However, it was shown
over a century ago that activation of the immune system using the highly immunogenic
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Coley’s toxin induced a potent systemic inflammatory response that helped to control
tumor growth and in some cases to eradicate solid tumors (6), demonstrating that if
properly activated the immune system is capable of controlling and eliminating the
disease. This concept helped establish the immunotherapy approach for cancer treatment.
The purpose of cancer immunotherapy is to activate the immune system and to restore its
functionality, hoping that it will be able to eliminate the primary tumor and prevent its
metastatic spread.
Current therapies intended to boost the immune system involve administration of
cytokines: interleukin-2 (IL-2) and interferon alpha (IFN-!) are FDA-approved for
treatment of Kaposi’s sarcoma and multiple types of leukemia (7, 8). A second approach
of immunotherapy involves antibody-based treatment: Rituxan, Herceptin, Campath are
example of commercially antibodies available for treatment of various leukemias, nonHodgkin’s lymphoma, and colorectal cancer (9). Cancer vaccines are the latest strategy
for prevention and treatment ofcancer. Cancer vaccines are intended to induce an
endogenous, long-lasting tumor antigen-specific immune response. They involve the
processing of tumor antigens by APCs and the accompanying presentation to T cells.
Cancer vaccines include protein-containing vaccines, in which tumor-associated antigens
(10) are usually combined with either adjuvants to induce a strong immune response,
with irradiated autologous tumor cells, or with allogenic tumor cells lines transfected
with cytokine genes (e.g. GM-CSF, IL2). Additionally, DC-based vaccines are currently
under evaluation. Autologous DCs are activated in vitro, provided with the tumor-antigen
(either as peptide, or as mRNA or cDNA encoding the antigen), and re-injected into the
patient. DC-based vaccines have shown promising results in animal models and in the
2

clinical setting.
The success of cancer vaccines is partly restrained by the accumulation of a group
of myeloid cells with immune suppressive activity. These cells can take up antigen
delivered by vaccination, present it to activated T cells and thereby inhibit the same
antigen-specific T cells that the vaccination strategy is aiming to activate (11). This
makes even the most effective antigen-delivery strategy ineffective because cancer
patients or animals can have considerable numbers of these myeloid-derived suppressor
cells. Reducing the numbers of these suppressive cells and/or inhibiting their suppressive
factors have been demonstrated to improve the efficacy of immunotherapy in both animal
models and cancer patients (12). This inhibitory population presents one of the many
roadblocks to the success of cancer immunotherapy and their elimination is a priority for
cancer patients who are candidates for active immunotherapy.

Identification and Definition of MDSC
A suppressive myeloid cell population associated with tumor development and
immunosuppression was described three decades ago (13). The first reports demonstrated
that administration of a Gr-1 specific antibody slowed the growth of an experimental
tumor. It was later found that the Gr-1 antibody eliminated both polymorphonuclear and
mononuclear cells in the blood. The Gr-1+ cells were comprised of cells at different
stages of maturation along the myeloid differentiation pathway (14). This suppressive
population is referred to as myeloid-derived suppressor cells (MDSC). MDSCs are
characterized in mice by the co-expression of the myeloid-cell lineage differentiation
antigen Gr1 and CD11b, also known as !M-integrin (14, 15). Gr-1+CD11b+ cells are
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normally present in the bone marrow of healthy mice and accumulate in the spleen and
blood of tumor bearing mice (16–19). MDSCs lack the expression of cell-surface markers
that are specifically expressed by monocytes, macrophages or DCs, and comprise a
mixture of immature myeloid cells (IMC) that have the morphology of granulocytes or
monocytes and have been prevented from fully differentiating into mature cells (20). Gr1+CD11b+ IMC present in steady-state conditions are not able to induce suppression of
stimulated T cells, and in healthy animals, they can quickly differentiate into mature
granulocytes, macrophages or dendritic cells (DCs). Normal mouse bone marrow
contains 20–30% of cells with this phenotype, but these cells make up only a small
proportion (2–4%) of spleen cells and are absent from the lymph nodes. In tumor-bearing
animals, cells with this phenotype can make up 50-70% of all bone marrow cells and up
to 40% of all splenocytes (these percentages fluctuate in tumor models). The human
equivalents of mouse MDSC are most commonly defined as CD14–CD11b+CD33+ cells
or, more narrowly, as cells that express the common myeloid marker CD33 but lack the
expression of markers of mature myeloid and lymphoid cells, and of the MHC class II
molecule HLA-DR (21,22). In healthy individuals, IMCs constitute ~0.5% of peripheral
blood mononuclear cells (22); in the blood of patients with different types of cancer a
tenfold increase in MDSC numbers has been detected (21-24).
Although initial observations of MDSC expansion were made in the field of
cancer, an expansion of immunosuppressive myeloid cell population has been
documented in multiple pathological inflammatory conditions. The importance of MDSC
has transcended into other scientific fields and MDSC-related research has extended to
areas involving bacterial infections (25,31), parasitic infections (26-30), traumatic stress,
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transplantation and autoimmunity (32-33).

MDSC Expansion in Cancer
The past decade of research has failed to identify a single factor responsible for
expansion of MDSC. The expansion of MDSC is predominantly viewed as the result of
the combined effort of many different factors, including pro-inflammatory mediators. The
contribution of inflammation to tumor initiation and progression is an old concept. It was
proposed by pathologist Rudolf Virchow over 140 years ago (34). Evidence linking
inflammation and cancer comes from studies demonstrating that long-term users of
nonsteroidal anti-inflammatory drugs, including aspirin, are at a significantly lower risk
of developing colorectal (35), lung, stomach, esophageal (36), and breast (37) cancers. In
addition, the block of inflammatory mediators or signaling pathways regulating
inflammation reduces tumor incidence and delays tumor growth, whereas heightened
levels of proinflammatory mediators or adoptive transfer of inflammatory cells increases
tumor development (38). These observations support the notion of a causative
relationship between chronic inflammation and cancer onset and progression. The list of
inflammatory mediators implicated in MDSC expansion includes the complement protein
C5a, prostaglandins PGE2, and the family of calcium binding proteins S100A8/A9.
The anaphylatoxin C5a is a complement component and a potent chemoattractant
and inflammatory mediator. Studies with C5aR-deficient mice demonstrate the
contribution of C5a to tumor progression, as after tumor challenge C5aR-/- had lower
tumor volumes than littermate controls (38). C5a promotes the accumulation of MDSC
not only in tumor tissues, but in peripheral lymphoid organs as well. The ability to
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suppress T cells of MDSC from tumor-bearing C5aR-deficient was impaired and
consequently, tumor-bearing C5aR-/- had higher numbers of infiltrating CTLs in the
tumor tissue than wild type counterparts (38). A second set of potent inflammatory
mediators produced by many tumors and implicated in MDSC expansion are the PGE2
molecules. PGE2 synthesis begins with the COX-2 catalyzation of arachidonic acid to
prostaglandin G2 (PGG2), which is subsequently modified by PGE synthase to PGE2.
Mouse MDSC were shown to express all four PGE receptors and coculture of bone
marrow progenitors with receptor agonists induced the differentiation of precursors cells
into suppressive MDSC. Blocking the PGE2 pathway with COX-2 inhibitors in tumorbearing mice decreases the numbers of MDSC and delays progression of spontaneous
mammary carcinomas (39).
Myeloid progenitors express receptors for the S100 family members and
accumulating evidence confirms their role in MDSC expansion during infection and
inflammation. The S100 calcium-binding protein family comprises of 12 proteins that
serve as inflammatory mediators released by cells of myeloid origin. S100A8 and
S100A9 have been implicated in MDSC expansion. These proteins are released in
response to cell damage, infection, or inflammation, and function as pro-inflammatory
danger signals. When wild type mice were injected with complete Freud’s adjuvant
(CFA), a fivefold increase in the proportion of circulating MDCS was observed between
days 6 and 9 post-injection. In contrast, in S100A9 deficient mice, the number of
circulating MDSCs did not increase after the treatment and the proportion of MDSC in
the spleens of S100A9-/- mice after CFA challenge was threefold lower than challenged
wild type animals (40).
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S100 proteins-binding to their receptors activates nuclear factor kappa-lightchain-enhancer of activated B cells (NF-kB) in MDSC (41), and a potential function of
NF-KB in MDSC development has been proposed in microbial infections, during which
accumulation of MDSC appears to result from Toll-like receptor (TLR) signaling. A
recent study focused on polymicrobial sepsis in mice, induced by ligation of the cecum
and a double enterotomy, found dramatic MDSC accumulating in spleens and peripheral
lymph nodes after the procedure. MDSC accumulation did not occur in mice deficient for
MyD88, an adapter protein operating downstream of TLRs (except TLR 3) that transmits
signaling from the receptors. The ultimate target of MyD88 is the activation of NF-kB,
suggesting a possible involvement of NF-kB in the accumulation of MDSC, at least
during infection and tissue damage (31).
In cancer, the expansion of MDSC has been primarily attributed to the numerous
cytokines and growth factors produced by tumor cells. Primary evidence supporting this
conclusion derives from studies revealing a decline of circulating MDSC after surgical
resection of tumors, and by early experiments that showed that conditioned medium from
tumor cells cultured in vitro prevented the differentiation of hematopoietic progenitor
cells (HPC) into mature APCs (42, 43). The cytokines and growth factors implicated to
MDSC expansion include stem cell factor (SCF), IL-1!, macrophage colony-stimulating
factor (M-CSF), IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF),
vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-!), IL10, IL-12, and IL-13 (44). Most of these cytokines trigger signaling cascades that
converge in a common signaling pathway, the Janus tyrosine kinase (JAK) protein family
members and signal transducer and activator of transcription 3 (STAT3), which are
7

signaling molecules that are involved in cell survival, proliferation, differentiation and
apoptosis (45). STAT3 is a member of the STAT family of transcription factors which
consists of seven members: STAT-1, -2, -3, -4, -6, and the closely related STAT5A and
STAT5B (46-48). Engagement of cytokine receptors activates JAKs which subsequently
recruit and phosphorylate STAT members. STATs undergo homo- or heterodimerization with other STAT proteins followed by translocation to the nucleus. STATs
modulate the expression of genes involved in cell growth, survival and differentiation.
Abnormal activation of STAT3 during tumor progression is well documented.
STAT3 is constitutively activated in tumor cells (49) and in diverse tumor-infiltrating
immune cells (50), leading to inhibition of proinflammatory cytokine, reduced chemokine
production, and to the release of factors that downregulate the immune response. Hyper
activation of STAT3 is also observed in MDSCs from tumor-bearing mice (51), and its
persistent activation preventing myeloid progenitors from differentiating. An in vitro
study showed that exposure of hematopoietic progenitor cells (HPCs) to supernatants
from tumor-cell cultures results in the accumulation of Gr-1+CD11b+ MDSC and
diminution of mature DCs. Blocking of STAT3 activity in the HPCs restored their ability
to differentiate into mature DCs. These findings were further confirmed in vivo (40).
Thus, hyper-activation of STAT3 in MDSC promotes their expansion in tumor-bearing
animals; however other potential outcomes stemming from STAT3 signaling in MDSC
remain to be elucidated.

Suppressive Mechanisms of MDSC
MDSC-mediated suppression of T cell activation has been extensively studied and
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proven by many research groups. These immunosuppressive activities appear to require
direct contact with the target cell, suggesting that these suppressive activities function
through cell-surface receptors and/or through the release of short-lived soluble mediators.
Factors implicated in suppression of T-cell function include reactive oxygen species
(ROS), regulation of L-arginine metabolism, production of TGF-!, depletion of cysteine,
induction of T-regulatory cells (Treg), down regulation of L-selectin surface proteins on
T cells and others. (18,82-85,94)
1. ROS production
Increased production of ROS is one of the main characteristics of MDSC
(18,20,52-57). ROS are crucial immunosuppressive mediators; inhibition of ROS
generation abrogates the suppressive function of MDSC in vitro (18,52,54). ROS are
highly reactive molecules due to the presence of unpaired valence shell electrons.
Generation of ROS occurs as the normal byproduct of oxygen metabolism and include
such species as super oxide (O2-), hydrogen peroxide (H2O2), hydroxyl radical (OH-),
hypochlorous acid (HOCl-), and peroxynitrite (ONOO-). Traditionally ROS are known
for their propensity to cause oxidative damage to nucleic acids, proteins and lipids; this
property is exploited by phagocytes to destroy invading pathogens. ROS also play a
regulatory role in signal transduction and gene expression.
The primary stimuli promoting ROS production in MDSC may be contact with
other cells. One study demonstrated that cell-cell interactions mediated by the integrins
CD11b, CD18 and CD29 significantly increased ROS production by MDSC (18). Thus,
adhesion molecules may contribute to MDSC-generation of ROS. Our lab has
demonstrated the significance of ROS generation by MDSC; the ROS molecule
9

peroxynitrite produced during direct contact with T cells resulted in nitration of the T-cell
receptor and CD8 molecules, altering specific peptide binding and rendering T cells
unresponsive to antigen-specific stimulation (12). Peroxynitrite is produced by the
chemical reaction between nitric oxide (NO) and O2-; it is one of the most powerful
oxidants that are produced in the body capable of inducing the nitration and nitrosylation
of the amino acids cysteine, methionine, tryptophan and tyrosine (63).
Although studies have suggested that ROS molecules are important factors in
tumor-mediated immune suppression, the mechanism leading to generation of ROS by
MDSC remains to be elucidated. The mitochondria and various oxidative enzymes can
generate ROS. The main source of ROS in leukocytes is a multi-subunit enzyme called
NADPH oxidase (NOX2), a complex that generates O2- in the one-electron reduction of
O2 using electrons supplied by NADPH after activation of its various components (58).
The oxidase complex consists of two membrane-bound proteins, gp91phox and p22phox,
cytosolic components p47phox, p67phox, p40phox, and a small GTPase protein Rac1 or Rac2
(58). The phagocyte NOX2 plays a key role in innate immune responses against
microbial pathogens by generating ROS that act as powerful microbicidal agents (59).
Sustained NOX2 activity requires continuous renewal of the enzyme complex; without it
rapid deactivation occurs (60). The activation of the complex, which is essential for its
full functionality, requires phosphorylation of the cytosolic components and their
translocation to the plasma membrane where the generation of O2- takes place (61). The
assembly and activation of the NOX2 complex can be induced by pro-inflammatory
cytokines, such as GM-CSF and TNF-alpha (62). Cell adhesion molecules and integrin
engagement are also capable stimulants of NOX2-dependent ROS generation (160)
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2. Metabolism of amino acid L-arginine
Metabolism of the amino acid L-arginine has been implicated in the suppressive
activity of MDSC. Metabolic manipulation of L-arginine is a survival strategy conserved
in lower organisms (64). This strategy is exploited by MDSC to limit the expansion and
function of T cells. L-arginine serves as a substrate for two distinct but related enzymes
arginase and inducible nitric oxide synthase.
A) Arginase (ARG): The importance of this enzyme in tumor progression is reflected by
the observation that its inhibition slows the growth of a lung carcinoma in a dosedependent manner (65). Two distinct isoforms, Arg1 and Arg2, have been identified in
mammals; they are encoded by different genes and are located in the cytoplasm and
mitochondria, respectively. Arg1 is primarily located in the cytosol of hepatocytes and is
an important component of the urea cycle. Arg1 expression is induced in myeloid cells by
exposure to the Th2 cytokines IL-4 or IL-13 (66, 67), TGF-! (68), and GM-CSF (69).
Arg2, also known as kidney-type arginase, is constitutively expressed in the mitochondria
of various cell types, including renal cells, neurons, macrophages and enterocytes.
Arginases hydrolyse the amino acid L-arginine to L-ornithine and urea. L-Ornithine is a
precursor for the synthesis of polyamines by the ornithine decarboxylase (ODC)
pathway; polyamines have an anti-inflammatory role and inhibit the release of proinflammatory cytokines from monocytes (70).
The primary consequence of arginase upregulation in MDSC is the depletion of
L-arginine from their surroundings. In the absence of L-arginine, T cells cultured in vitro
fail to proliferate upon stimulation and fail to produce interferon gamma (IFN-!) (71). Larginine deprivation triggers several negative effects on T cell activation. First, T cells
11

deprived of L-arginine are deficient for CD3! chain and become arrested in the Go–G1
phase of the cell cycle (72). Second, the expression of cell cycle regulators cyclin D3 and
cyclin-dependent kinase 4 is also compromised (73). Finally, L-arginine starvation can
result in phosphorylation of eukaryotic translation initiation factor 2 (EIF2a), halting the
initiation of translation and repressing protein synthesis (74).
B) Nitric Oxide Synthase (NOS). L-arginine is also the substrate for a family of
enzymes known as NOS. These enzymes catalyse the reaction between oxygen and Larginine, generating L-citrulline and NO. Three distinct isoforms of NOS are the products
of different genes: NOS1 is primarily found in neuronal tissue; NOS2 is the inducible
isoform (also known as iNOS) and is found in various cells of the immune system,
including several types of myeloid cell. NOS3 is found in endothelial cells (75-77).
NOS inhibitors reverse immune suppression demonstrating immunoregulatory
properties of NO (78). NO operates through various mechanisms to suppress T cell
function. It interferes with the IL-2R-signalling pathway by blocking the phosphorylation
of signal-transducing pathways coupled to IL-2R and by altering the stability of IL-2
mRNA (79). Exposure to NO can also lead to cellular apoptosis (80). NO also interferes
with the cytotoxic effector phase (81). NO causes mRNA instability of Ras, a critical
molecule in the signal transduction cascade from TCR activation to cytolytic granule
release, resulting in inefficient exocytosis of the cytotoxic granules. Through this
mechanism, NO prevents activated lymphocytes from killing target cells.
3. Production of TGF-!
The immunosuppressive molecule TGF-" has also been implicated to MDSC
function. TGF-" is a cytokine with multiple immunosuppressive properties (82).
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Inhibition of TGF-! by antibody or soluble receptor inhibits tumor growth in vivo (83)
and T cells that do not respond to TGF-! were resistant to implanted tumor cell lines B16
and EL4 (84). A separate study suggested that MDSC are the main source of TGF-! in
tumor-bearing animals. In this study, MDSC induced by a mouse fibrosarcoma or colon
carcinoma when stimulated with IL-13 through the IL-13R" are activated to produce
TGF-! (85) In the presence of TGF-!1, antigen-stimulated T cells lose their cytolytic
activity. This evidence suggests that direct action of TGF-! on T cells suppresses
antitumor T cell activity and results in uncontrolled outgrowth of tumor cells.
4. Cysteine depletion.
A new proposed mechanism of immune regulation employed by MDSC is
deprivation of the amino acid cysteine. Cysteine is essential for T cell activation. T
lymphocytes lack the enzyme to generate cysteine and must import it from APCs during
antigen presentation. Macrophages and DCs import cystine, a cysteine precursor, from
their environment and metabolize it into cysteine. MDSC import cystine at comparable
rates as APCs but are unable to export cysteine into their surroundings. Thus, through the
competition for cystine, MDSC make their immediate environment cysteine-deficient and
T cells are unable to synthesize the necessary proteins for activation (86)
5. Induction of regulatory T cells
MDSC-induction of forkhead box P3 (FOXP3)+ Tregs has been proposed to
contribute to the persistent tolerance to tumor-specific antigens in tumor-bearing host.
However, conflicting reports on this subject have been presented. In mice bearing 1D8
ovarian tumours, the MDSC-mediated induction of Tregs required the expression of the costimulatory B7 family member, B7H-1 (also known as CD80), by MDSCs (87). In a
13

mouse model of lymphoma, MDSCs were shown to induce Tregs expansion through a
mechanism that involved arginase 1 and the capture, processing and presentation of
tumor-associated antigens by MDSCs, but was independent of TGF! (88). By contrast,
another group found that the percentage of Treg was invariably high throughout tumour
growth and did not relate to the kinetics of expansion of the MDSC population,
suggesting that MDSCs were not involved in Tregs induction (89). Although it seems
possible that MDSCs are involved in Tregs differentiation through production of cytokines
or through direct cell–cell interactions, further work is required to resolve these
conflicting reports and to determine the physiological relevance of these studies.
6. Downregulation of L-selectin
Antigen naïve T cells typically encounter antigen in draining lymph nodes and
inside tumor tissues (90,91). T cells are directed to these sites because they express high
levels of L-selectin (CD62L), a selectin family member that facilitates the extravasation
of leukocytes from the blood and lymphatics to lymph nodes and inflammatory locales,
such as tumor microenvironments (92,93). However, in cancer patients and animal
models, circulating naïve lymphocytes typically express low levels of L-selectin.
Evidence linking MDSC to the reduced levels of L-selectin include the inverse
correlation of L-selectin expression in T cells with the number of MDSC in tumor
bearing mice (94). Furthermore, CD4+ or CD8+ T cells co-cultured with MDSC had an Lselectin low phenotype, demonstrating that MDSC directly down-regulate T cell
expression of L-selectin. Hence, this study proposed that MDSC block T cell activation
by inhibiting T cell trafficking to antigen-containing sites.

Origin and Functional Polarization of TAM
14

In addition to MDSC, tumor-associated macrophages (TAMs) are a population of
myeloid cells that negatively regulate antitumor immune responses. The relationship
between TAMs and MDSCs is not completely defined but, as discussed below, TAMs
have been suggested to partly derive from or be related to MDSCs. Numerous studies
have found a direct correlation between the presence of macrophages in tumor tissues and
poor prognosis in multiple mouse and human malignancies (95-98) making the presence
of TAMs a key prognosticator of cancer progression. Our current knowledge regarding
the origin of macrophages at the tumor site remains incomplete. The recruitment of
monocytes to neoplastic tissues is a contributing factor to the accumulation of TAMs
(98). Monocytes originate from the bone marrow and enter the circulation where they
undergo maturation. Differentiation into macrophages happens once mature monocytes
migrate into the tissues and involves a list of changes: the cell enlarges five- to ten-fold;
phagocytic ability is enhanced; production of hydrolytic enzymes increases, and gains the
potential to secrete large numbers of inflammatory factors (99).
During the course of an immune response macrophages become activated and,
depending on the cytokine network they encounter, become either highly effective in
destroying potential pathogens and activating the adaptive immune system, or become
attenuators of the inflammatory response. These two opposing polarization states are
classified as M1 or M2 polarization. M1 macrophages, also known as classically
activated macrophages, are powerful effectors against invading pathogens and tumor
cells, secrete inflammatory cytokines and efficiently activate the Th1 response. M1
macrophages are induced in response to IFN-! alone or together with microbial agents
(i.e. LPS) (100). In contrast to M1 macrophages, the alternatively activated M2
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macrophage is induced by anti-inflammatory molecules, such as cytokines IL-4, IL-13,
IL-10 and glucocorticoids. M2 macrophages mediate wound repair, tissue remodeling,
angiogenesis, and suppress Th1 immunity (101). While the M1 phenotype is
characterized by production of cytokines IL-12, IL-6, TNF-!, the M2 macrophage
classically produces IL-10 and TGF-". In addition to their distinct patterns of cytokine
expression, metabolism of L-arginine is also a distinguishable characteristic of polarized
macrophages: activation of NOS2 is a hallmark of M1 macrophages whereas ARG1
activation is one of the most specific markers of M2 polarization.
It

has

been

suggested

that

macrophages

differentiating

within

the

immunosuppressive environment of a tumor display an M2-like phenotype, although it is
not clear whether this suggestion can be generalized and applicable to TAMs in the
different regions of a tumor. However, TAMs do appear to share a number of similarities
with M2 macrophages include expression of immunosuppressive factors (IL-10, TGF-",
ARG1) while producing low levels of M1 macrophage–mediated inflammation mediators
i.e. IL-12, tumor necrosis factor alpha (TNF-!), IL-6, iNOS (102, 103, 104).
Angiogenesis is an M2-associated function, and TAMs are associated with angiogenesis
through the production of angiogenic factors (VEGF, CCL2, FGF2, CXCL8, CXCL1,
and CXCL2) (102, 105, 106, 107). TAMs express high levels of the mannose receptor, a
signature of M2 polarization. TAMs. TAMs are poor producers of both NO and ROS,
hallmark characteristics of microbicidal M1 macrophages, and are poor antigenpresenting cells. In addition, TAMs display several pro-tumoural functions and secrete
factors that contribute to matrix remodeling (TGF-", CCL2, matrix metalloproteinases
such as MMP9) (102, 108), and have been observed to recruit Tregs into tumor tissues
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(through secretion of CCL22) (109).
Accumulation of TAMs in neoplastic tissues appears to be driven by the action of
tumor-derived cytokines. VEGF and M-CSF promote monocytic migration and survival.
IL-10 promotes monocyte differentiation into macrophages and blocks their
differentiation to DCs. Additionally, chemokines produced by tumor cells (CCL2 being
the most frequently found in tumors) appear to play a fundamental role in the recruitment
of monocytes to the tumor site. Moreover, a relationship between MDSC and TAMs has
also been suggested by recent studies; splenic Gr-1+ cells isolated from tumor-bearing
animals transferred into new tumor-bearing hosts were shown to reach the tumor site and
become TAMs characterized by high STAT1 phosphorylation and constitutive expression
of ARG1 and NOS2 (78). This study indicates that, in addition to monocytes, circulating
MDSC are plausible precursors of TAMs.

Role of Hypoxia in Accumulation of TAMs
Hypoxia is the state of oxygen deprivation and a characteristic feature of growing
tumors. Hypoxic areas arise due to rapid oxygen-consumption rate by cancer cells along
with insufficient oxygen supply. This disparity is caused partly when solid tumors rapidly
outgrow their blood supply, leaving portions of the tumor with areas where the oxygen
concentration is significantly lower than in healthy tissues. For instance, oxygen partial
pressure (pO2) measurements in squamous cell carcinomas from cervical cancer patients
showed a four-fold reduction compared to normal cervix tissue (8 mmHg in tumors, 42
mmHg in normal cervix) (117). The difference in oxygen tension between tumor tissues
and the circulation is even greater, as pO2 in alveoli reaches 100 mm Hg (118). The
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oxygenation status and extent of hypoxia were independent of clinical size, tumor stage
and grade of malignancy (117).
Cells have developed mechanisms to cope with hypoxic stress. The principal
element allowing cells to adapt to hypoxic stress is the hypoxia-inducible factor (HIF)-1.
HIF1 is a heterodimeric transcription factor consisting of a constitutively expressed HIF1! subunit and the oxygen-tension-regulated HIF-1" subunit. In the presence of oxygen,
the HIF1" protein is quickly targeted for ubiquitination and degradation but accumulates
in response to declining oxygen levels (119,120). Increased HIF1" protein stability and
activity of the HIF1 complex, in turn, regulate the transcription of a vast array of genes
involved in tumor-cell survival: oxygen delivery, angiogenesis, and energy conservation
(119,121).
Macrophages are also affected by low oxygen tension. In mononuclear cells,
hypoxia promotes production of growth factors and cytokines linked to tumor
angiogenesis and progression. VEGF is one such example; interestingly, VEGF
expression by TAMs is confined only to hypoxic areas in tumor sections and is not
detected in well-vascularized sections (122). In vitro studies with macrophages cultured
under hypoxia have shown their increased production of key proangiogenic growth
factors (123,124). Hypoxia is also capable of modifying immune responses from
macrophages, as various inflammatory and anti-inflammatory mediators are increased in
macrophages after hypoxic exposure (125). Furthermore, the presence of TAMs in the
tumor-microenvironment may be controlled in part by tumor hypoxia. Corroborating this
hypothesis is the observation that TAMs primarily accumulate at highest densities in
hypoxic areas of solid tumors, a phenomenon reported in breast (110), prostate (111) and
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ovarian tumors (112). Chemoattractants released by tumor cells, such as endothelin-2 and
EMAPII, have been associated with TAM recruitment to hypoxic sites (113). In addition,
hypoxia impedes the motility of macrophage once they reach hypoxic areas by inducing
down-regulation of chemokine receptors CCR2 and CCR5 (114,115) and up-regulation
of the enzyme mitogen-activated protein kinase phosphatase (MKP-1) which inhibits
chemotaxis signaling (116).
Although there is plenty of information on the migration and activation of
macrophages induced by hypoxia, the literature contains rather little of the effect of
hypoxia on the differentiation of myeloid cells. Recently, hypoxia was reported to inhibit
the maturation of bone marrow progenitors into functional DCs (126). This observation
prompts the speculation that macrophage differentiation from progenitors could also be
disturbed. Taking this idea further, it is quite plausible that tumor hypoxia may regulate
the differentiation of MDSC into TAMs.

Statement of Purpose
The major goal of our laboratory is to understand the mechanisms of tumorassociated immunosuppression and the development of new and effective cancer
vaccines. MDSC is one of the major factors impeding host immune responses to tumor.
These cells accumulate in peripheral lymphoid organs and in tumor tissues where they
suppress the activation of T cells helping tumors avoid the effector arm of the adaptive
immune system. The mechanisms of suppression traditionally ascribed to MDSC are
enhanced ROS productivity and regulation of the amino acid L-arginine by its
metabolizing enzymes Arg and iNOS. Although each pathway exerts different
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consequences on T cell biology, both pathways converge on the same ultimate outcome:
the inhibition of T cell function.
The objective of this project was to determine the suppressive pathways by which
MDSC render T cells ineffective in tumor bearing animals and cancer patients. The
aspects investigated were the identification of suppressive nature of MDSC and its
regulation,

first

in

peripheral

lymphoid

organ

and

second

in

the

tumor

mocroenvironment. For MDSC-mediated T cell suppression in lymphoid organs, we
focused on investigating increased ROS productivity in splenic MDSC, and whether
STAT3 protein played a role in this modulation. For T cell suppression in the tumor
microenvironment we concentrated on the ability of MDSC to modulate L-arginine
metabolism and whether hypoxia, a prominent feature of tumor tissues, controlled the
suppressive factors involved in MDSC-mediated suppression. Investigating the role of
hypoxia led us to further dissect the role of HIF-1! in differentiation and expansion of
MDSC in tumor-bearing hosts.

20

MATERIALS AND METHODS

Mice and tumor models.
BALB/c and C57BL/6 mice (6–8 wk of age) were obtained from the National
Cancer Institute. Mice were kept in pathogen-free conditions. OT-1 TCR-transgenic mice
(C57Bl/6-Tg(TCRaTCRb)1100mjb),

gp91phox–/–(B6.129S6-Cybbtm1Din),

CD45.1+

congeneic mice (B6.SJL-PtrcaPep3b/BoyJ), HIF-1!flox/flox (B6.129-Hif1atm3Rsjo/JE),
and Mx1-Cre+/- (C57BL/6J-Tg(Mx1-cre)1Cgn/J) were purchased from Jackson
Laboratories. 2C TCR transgenic mice have been described previously (10). STAT3-/mice (LysMcre/Stat3flox/-) were generated by Dr. S. Akira (Osaka University, Japan).
LysMcre mice were crossed with Stat3flox/+ mice to generate LysMcre/Stat3flox/- mice
(experimental group). LysMcre/Stat3flox/+ mice from these crosses were used as littermate
controls.
The following subcutaneous tumor models were used in this study. In BALB/c mice:
DA3 mammary carcinoma (provided by D. Lopez, University of Miami, FL), CT26 colon
carcinoma (American Type Culture Collection (ATCC), Manassas, VA), and MethA
sarcoma (provided by L. J. Old, Ludwig Institute for Cancer Research, New York, NY).
In C57BL/6 mice: EL4 thymoma (ATCC), Lewis Lung Carcinoma (LLC), MC38 colon
carcinoma (provided by I. Turkova, University of Pittsburgh, Pittsburgh, PA), and C3
sarcoma (provided by W. Kast, University of Southern California, Los Angeles, CA).
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The number of tumor cells injected s.c. was different for each model and was selected
based on the ability to form a tumor with 1.5 cm diameter within 2-3 weeks of injection.
EL-4 ascitic tumor was generated by injecting 3x105 tumor cells i.p. into C57BL/6 mice.
mCC10TAg transgene model of lung cancer was described previously (Magdaleno et al.,
1997).

Reagents.
Arginase inhibitor NW-hydroxyl-nor-L-arginine (nor-NOHA) and inducible NO
synthase

(iNOS)

inhibitor

NG-monomethyl-L-arginine

(L-NMMA)

were

from

Calbiochem. 2C-specific (H-2Kb, SIYRYYGL) and control (H-2Kb RAHYNIVTF)
peptides were obtained from QCB. Dichlorodihydrofluorescein diacetate (DCFDA) was
purchased from Molecular Probes (Eugene, OR). Anti-STAT3, phospho-STAT3
antibodies were obtained from Cell Signaling Technology (Boston, MA); antibodies
against gp91phox and p47phox were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA); anti- HIF-1! antibody from R&D systems; biotinylated anti-Gr-1 antibody from
BD Pharmingen; biotinylated anti-F4/80 antibody from Serotec (Raleigh, NC).
MiniMACS magnetic beads conjugated with streptavidin (Miltenyi Biotec, Auburn, CA).
All other antibodies used for flow cytometry were purchased from BD Biosciences (San
Jose, CA).

Patients.
Six patients (47-78 years old) with resectable T3 or T4 and N2b stage of head and
neck cancer (HNC) were enrolled in the study after signing IRB approved consent.
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Patients did not receive radiation or chemotherapy for at least 3 months prior to sample
collection. Peripheral blood and tumor tissues were collected at the time of surgery from
all patients. In order to obtain single cell suspensions from tumors, solid tissue was
subjected to 1 hr enzymatic digestion using hyaluronidase (0.1 mg/ml; Sigma)
collagenase (2 mg/ml; Sigma), DNase (600 U/ml; Sigma) and protease (0.2 mg/ml;
Sigma) in RPMI 1640. The digested tissue was passed through a 70 !m mesh,
erythrocytes removed by hypotonic lysis, and washed thoroughly to remove debris.
Mononuclear cell suspensions were obtained from whole blood using a density gradient
centrifugation. All cell samples were analyzed within 3 hr following collection. Cells
were loaded with DCFDA and stimulated with PMA where appropriate. To identify live
MDSC, mononuclear cells were labeled with PerCP-Cy5.5-conjugated anti-CD14, APCconjugated anti-CD11b and PE-Cy-7-conjugated anti-CD33. Antibody labeled cells were
finally resuspended in DAPI buffer to identify viable cells before data collection. To
detect iNOS in MDSC, cells after surface staining with antibodies described above were
fixed, permeabilized using FixPerm buffer (BD Biosciences), and then stained with FITC
conjugated anti-iNOS antibody. Cells were evaluated by multi-color flow cytometry
using a LSRII flow cytometer (BD Biosciences, Mountain View, CA). At least 100,000
cells were collected from each parameter in order to obtain reliable data. Analysis of the
samples was carried out essentially as described elsewhere (12).

Cell culture and hypoxic conditions.
MDSC were cultured in complete RPMI media containing 10 ng/mL GMCSF.
Hypoxic environment (1% O2 with 5% CO2) was created and maintained using C23

Chamber Hypoxic Incubator Chamber (BioSpherix, NY).

Isolation of mouse cells.
To collect MDSC, single cell suspensions were prepared from spleens, and red
cells were removed using ammonium chloride lysis buffer. MDSC were isolated by cell
sorting on a FACSAria cell sorter using staining with APC-conjugated anti-Gr-1 and PEconjugated anti-CD11b antibodies (BD Pharmingen). In some experiments splenic
MDSC were isolated using magnetic beads conjugated with streptavidin (Miltenyi
Biotec, Auburn, CA) and biotinylated anti-Gr-1 antibody. MDSC isolation from lung
tumors. Lungs were collected from CC10Tg mice with lung tumor and the blood in the
lungs was cleared by perfusion through the pulmonary artery with saline containing 2mM
EDTA. Lung tumor tissues were dissected and digested with collagenase XI (0.7 mg/ml;
Sigma-Aldrich) and type IV bovine pancreatic DNase (30 mg/ml; Sigma-Aldrich) for 45
min at 37°C water bath. Remaining red cells were lysed by ACK and dead cells were
removed by Lympholyte M. Gr-1+ cells were isolated by using biotinylated anti-Gr1antibody and streptavidin microbeads on MiniMACS columns (MiltenyiBiotec, Auburn,
CA). To collect peritoneal macrophages, mice were injected intraperitoneally (i.p.) with
1 mL thiglycollate (DIFCO Laboratories, Detroit, MI). Three days later, peritoneal cells
were obtained by peritoneal lavage. Peritoneal macrophages were harvested using
biotinylated anti-F4/80 Ab (Serotec, Raleigh, NC) and magnetic isolation. To harvest
cells from ascitic tumors, mice were sacrificed and the peritoneum was washed with 10
ml of ice-cold PBS; cells were then aspirated and placed on ice immediately.
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ROS detection, arginase activity, and NO production.
Oxidation-sensitive dye DCFDA was used to measure ROS production by
MDSC. Cells were incubated at 37°C in RPMI in the presence of 2.5 µM DCFDA for 30
min. For PMA-induced activation, cells were simultaneously cultured, along with
DCFDA, with 30 ng/ml PMA (Sigma). Cells were then labeled with anti-Gr-1 and antiCD11b Abs on ice and evaluated by flow cytometry. Production of H2O2 was quantified
using Amplex® Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen) as
recommended by manufacturer. Briefly, 25 x 103 cells were resuspended in Hanks
Balanced Salt Solution (Sigma). After addition of PMA (30 ng/ml), the absorbance at 560
nm was measured using a microplate plate reader (Bio-Rad, Hercules, CA) at 37 °C.
Absorbance results were normalized to a standard curve generated by serial dilutions of
20 mM H2O2.
Arginase activity was measured in cell lysates, as previously described (32). Briefly, cells
were lysed for 30 min with 0.1% Triton X-100. To 100 µl of protein lysate (25 µg/ml),
100 µl of 25 mM Tris-HCl and 10 µl of 10 mM MnCl2 were added, and the enzyme was
activated by heating for 10 min at 56°C. Arginine hydrolysis was conducted by
incubating the lysate with 100 µl of 0.5 M L-arginine (pH 9.7) at 37°C for 120 min. The
reaction was stopped with 900 µl of H2SO4 (96%)/H3PO4 (85%)/H2O (1/3/7, v/v/v). The
urea concentration was measured at 540 nm after addition of 40 µl of !isonitrosopropiophenone (dissolved in 100% ethanol), followed by heating at 95°C for 30
min. One unit of enzyme activity is defined as the amount of enzyme that catalyzes the
formation of 1 µmol urea per min.
To detect nitrites equal volumes of culture supernatants (100 µl) were mixed with Greiss
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reagent. After 10-min incubation at room temperature, the absorbance at 550 nm was
measured using microplate plate reader (Bio-Rad). Nitrite concentrations were
determined by comparing the absorbance values for the test samples to a standard curve
generated by serial dilution of 0.25 mM sodium nitrite.

Quantative Real-Time PCR (qRT-PCR)
RNA was extracted with Trizol (Invitrogen, Frederick, MD); cDNA was
synthesized and used for the evaluation of gene expression as described previously
(Nefedova et al., 2004). To detect Arg1, iNOS, and NOX2 subunits, PCR was performed
with 2 µl cDNA, TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City,
CA), and target gene assay mix containing sequence-specific primers and 6carboxyfluorescein (6-FAM) dye–labeled TaqMan minor groove binder (MGB) probe
(Applied Biosystems). Amplification with 18S endogenous control assay mix was used
for controls. PCR was carried out in triplicate for each sample. Data quantitation was
performed using the relative standard curve method. Expression levels of the genes were
normalized by 18S mRNA. To detect expression of cytokines IL-6, TGF-!, IL-12, IL-10,
PCR was performed with 12.5 µl SYBR Master Mixture (Applied Biosystems, Foster
City,

CA,

USA),

and

the

following

ATCCAGTTGCCTTCTTGGGACTGA-3’;
ATGCAGCAAGTGGGCATGTGTT -3’;
TACGTCAGACATTCCGGGAAGCAGT-3’;

primers:

(sense+):

IL-6:

5’-

IL-12:

5’-

TGF-!:

5’-

IL-10:

5’-

TACCAAAGCCACAAAGCAGCCT-3’. The expression of IL-6, TGF-!, IL-12, and IL10 were normalized to !-actin. (5‘-ACCGCTCGTTGCCAATAGTGATGA-3’)
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Western blotting.
Cells were lysed in TNE buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM
EDTA) containing 1% NP40 in the presence of protease and phosphatase inhibitors.
Isolation of membrane and cytoplasmic compartments was achieved using Qproteome
Cell Compartment Kit (Qiagen Inc., Valencia, CA) according to manufacturer’s
instructions. Protein lysates were subjected to 8% SDS-PAGE and transferred to PVDF
membranes. Membranes were probed with appropriate primary Abs overnight at 4°C.
Membranes were washed and incubated overnight at 4°C with secondary Ab conjugated
with peroxidase. Results were visualized by chemiluminescence detection using a
commercial kit (Amersham Biosciences). To confirm equal loading, membranes were
stripped and reprobed with antibody against !-actin (Santa Cruz Biotechonology, Santa
Cruz, CA)

Evaluation of T cell function.
Proliferation. Splenocytes from either 2C transgenic mice or OT-1 mice, depleted
of red cells, were placed in triplicates into U-bottom 96-well plate (1 x 105/well). For
antigen-specific responses, splenocytes were cultured in the presence of cognate antigen
(2C-specific peptide SIYRYYGL or OT-1 specific peptide SIINFEKL) and cultured for a
total of 72 hr. For anti-CD3/CD28 antibody-induced T cell proliferation, splenocytes
were cultured in the presence of 1 µg/ml anti-CD3 Ab and 5 µg/ml anti-CD28 Ab.
Eighteen hours before harvesting, cells were pulsed with 3H-thymidine (1 µCi/well;
Amersham Biosciences). 3H-Thymidine uptake was counted using a liquid scintillation

27

counter and expressed as counts per minute (CPM). IFN-! production. The number of
IFN-!-producing cells in response to cognate antigens or CD3/CD28 antibodies was
evaluated in ELISPOT assay as described (10). Each well contained 1 x 105 splenocytes.
The number of spots was counted in triplicates and calculated by an automatic ELISPOT
counter (Cellular Technology).

EMSA.
Nuclear extracts were prepared in hypertonic buffer containing 20 mM HEPES
(pH 7.9), 420 mM NaCl, 1 mM EGTA, 1 mM EDTA, 20% glycerol, 1 mM DTT, and
protease and phosphatase inhibitors cocktail. Extracts were normalized for total protein,
and 5 µg of protein was incubated with 32P-labeled probes containing: STAT1 and
STAT3 sequence, 5’-AGCTTCATTTCCCAGAAATCCCTA-3’; p47phox sequence, 5’AGCTTCATTTCCCAGATATCCCTA-3’;

or

mutant

sequence,

5’-

AGCTTCATTGCACTCATATCCCTA-3’. Protein-DNA complexes were resolved by
nondenaturing PAGE and detected by autoradiography.

Chromatin Immunoprecipitation (ChIP) assay.
32D cells were cultured in 10% FBS RPMI 1640, supplemented with IL-3.
Preparation of chromatin-DNA and ChIP assay were performed using a kit from Upstate
Biotechnology (Lake Placid, NY), anti-STAT3 antibody from Cell Signaling
Technology, normal rabbit IgG from Santa Cruz Biotechnology, protein A
agarose/salmon sperm DNA from Upstate (Millipore, Billerica, MA). Sonication was
performed using Branson Sonifier (model 450, VWR Scientific, West Chester, PA). After
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reversal of crosslinking, purified DNA was subjected to PCR with the following primers
spanning

the

potential

STAT3

binding

AGTTAAAGGCATGTGCCACCACTG

site

in
-3’,

the

p47phox promoter:
and

5’5’-

TACACCTGCGTGCAGACATCATCT-3’.
Primers for !-actin: 5’-TAGGGTGTAGACTCTTTGCAGCCA-3’, and 5’AGCGTCTGGTTCCCAATACTGTGT-3’.

Experiments with embryonic stem (ES) cells.
R1 ES cells were transfected with empty RcCMV-Neo vector (R1-C) or STAT3c
plasmid (R1-Stat3C)(18) using lipofectamin. ES transfectants were selected in DMEM
containing G418 (0.2 mg/mL), 15% ES cell certified FBS (Gibco, Rockville, MD),
eukocyte inhibitory factor (LIF; 1000 U, Chemocon, Temecula, CA), 0.1 mM
nonessential amino acid, 100 µM 2-mecaptoethenol, and 2 mM L-glutamine.

Statistics.
Statistical analysis was performed using non parametric Mann-Whitney test and
GraphPad Prism software (La Jolla, CA). In all cases p values were calculated using twosided t test.
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RESULTS

I. Suppressive Mechanism of MDSC in Peripheral Lymphoid Organs: Role of
NADPH Oxidase (NOX2) and Signal Transducer and Activator of Transcription 3
(STAT3)
ROS molecules have been implicated in the attenuation of T-cell immune
responses by MDSC (52,54,56). Treatment of MDSCs with ROS inhibitors (catalase and
uric acid) abrogated antigen-specific inhibition of CD8+ T-cells by splenic MDSC (18).
Neutralization of ROS with the H2O2 scavenger catalase improved the ability of MDSC
to differentiate to mature myeloid cells in vitro (127). These studies established critical
role of ROS in MDSC function. We thus intended to identify the source of ROS in
MDSC and the mechanism leading to its production. To this end we analyzed the
expression of the subunits of the NOX2 complex and its possible regulation by STAT3,
whose enhanced activity had been previously demonstrated in MDSC (51).

Hyper-production of ROS in splenic MDSC from tumor-bearing mice
We first addressed the question whether up-regulation of ROS in splenic MDSC was a
wide-spread phenomenon observed in several different tumor models, since prior studies
demonstrating increased ROS generation by MDSC were carried using a select number of
models. We tested seven mouse tumor models of sarcomas, thymoma, colon, mammary,
and lung carcinomas on BALB/c and C57BL/6 strains. A different number of tumor cells
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were injected s.c. in order to allow for the development of similar size tumors (1.5 cm in
diameter) within 3 weeks after tumor inoculation. This time frame was selected as it is
widely used in most studies of tumor-associated immune suppression. Splenocytes were
isolated, stimulated with PMA and labeled with anti-Gr-1 and anti-CD11b antibodies to
identify MDSC in tumor-bearing mice or immature myeloid cells (IMC) in naïve tumorfree mice. ROS levels were measured using the oxidation-sensitive fluorescent dye
DCFDA within the population of Gr-1+CD11b+ MDSC or IMC. MDSC from all tumor
models without exception demonstrated a significantly higher level of ROS than their
control counterparts (Fig. 1A). To verify those observations using a different
experimental system, we measured the level of hydrogen peroxide (H2O2) in MDSC
isolated from spleens of CT26 and EL4 tumor-bearing mice. In both tumor models,
MDSC produced substantially higher level of H2O2 than IMC (Fig. 1B). Higher level ( p
< 0.05) of ROS production by MDSC was also detected in response to other stimuli
(ionomycin and LPS) indicating that this effect is not restricted to PMA (Fig. 1C).
Furthermore, ROS levels were measured in MDSC during dynamic tumor growth. The
significant increase of ROS levels in MDSC became most prominent 3 weeks after tumor
inoculation (Fig. 1D) which coincides with substantial expansion of MDSC (unpublished
observations) in these models.

ROS generation by MDSC in peripheral blood samples of head and neck cancer
patients
To extend our studies to the clinic, we evaluated ROS levels in MDSC from
patients with stage III head and neck cancer (HNC). In humans, MDSC are identifiable as
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CD11b+ CD14– CD33+ cells and previous studies have shown that these cells have
functional characteristics of MDSC (128,129). Peripheral blood mononuclear cells from
healthy volunteers and patients were labeled with APC-conjugated anti-CD11b, PerCpCy5.5-conjugated CD14 and PE-Cy7-conjugated anti-CD33 antibodies and loaded with
DCFDA. ROS levels were evaluated within the population of CD11b+ CD14– CD33+
cells. MDSC in peripheral blood from patients demonstrated an approximately five-fold
higher level of ROS upregulation following PMA-stimulation compared to cells with the
same phenotype from healthy volunteers (p=0.0165) (Fig. 2).

Increased transcription of NAPDH Oxidase controls ROS upregulation and
suppressive activity of peripheral MDSC.
Though ROS can be produced in cells by several different mechanisms, the
primary source of ROS in leukocytes is by NADPH oxidase (NOX2). The oxidase is a
multicomponent enzyme consisting of two membrane proteins, gp91phox and p22phox and
at least four cytosolic components: p47phox, p67phox, p40phox and a small G protein Rac
(58). We measured expression of these subunits in MDSC isolated from naïve tumor-free
and CT-26 tumor-bearing BALB/c mice using qRT-PCR. MDSC from tumor-bearing
mice had a substantially higher level of mRNA for several major NOX2 components.
However, the most prominent increase was observed in the level of expression of
gp91phox and p47phox (Fig. 3A). Increased expression of these genes was also observed in
two other tested tumor models (EL-4 and MC38) (Fig. 3B). The most significant increase
in gp91phox and p47phox expression was detected in mice 3 weeks after tumor inoculation,
which coincided with the time when the most elevated level of ROS was observed in
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these cells (Fig. 1D). In accordance with our PCR results, MDSC from tumor-bearing
mice had substantially higher level of p47phox and gp91phox proteins in whole cell lysates
than IMCs from naïve mice (Fig. 3C). Up-regulation of these proteins was also seen in
the membrane fraction of MDSC from tumor-bearing mice (Fig. 3D), which is possibly
indicative of an elevated activation status when compared to naive counterparts.
To investigate a direct contribution of NOX2 to the hyper-production of ROS we
used mice lacking gp91phox. These mice are used to study chronic granulomatous disease
(CGD), a recessive disorder characterized by a defective phagocyte respiratory burst
oxidase, life-threatening pyogenic infections and inflammatory granulomas (130). Gene
targeting was used to generate mice with a null allele of the 91 kD subunit of NADPH
Oxidase. The affected mice lack phagocyte O2- production, and manifest increased
susceptibility to bacterial and fungal infections. EL-4 tumor was established in wild-type
and gp91phox-deficient mice and the level of ROS was measured in MDSC 3 weeks after
tumor inoculation. In contrast to their wild-type counterparts, gp91phox-deficient MDSC
from tumor-bearing mice showed no increase in the level of ROS when compared to
MDSC from tumor-free mice (Fig. 4A); it’s also important to note that gp91phox-/- mice
smaller tumor growth compared to wild-type mice, though the differences were not
statistically significant (data not shown). We then asked whether lack of NOX2 activity
affected suppressive activity of MDSC as well as their inability to differentiate. Gr1+CD11b+ cells were isolated from spleens of naïve tumor-free mice, spleens of wild-type
EL-4 tumor-bearing mice and gp91phox-/- EL-4 tumor-bearing mice and their ability to
inhibit T-cell responses was compared. MDSC from tumor-bearing mice induced
significant suppression of IFN-! production and proliferation of antigen-specific CD8+T
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cells in response to stimulation with a specific peptide (Fig. 4B,C). In striking contrast
MDSC from NOX2 deficient mice failed to suppress T-cell function (Fig. 4B,C). To
evaluate the effect of NOX2 on MDSC differentiation, Gr-1+CD11b+ cells isolated from
wild-type and gp91phox-/- tumor-bearing mice were cultured in vitro for 5 days with GMCSF in the presence of tumor-cell-conditioned medium (TCCM). Almost 40% of MDSC
from wild-type mice retained the immature phenotype (Gr-1+CD11b+), with a small
proportion of cells differentiating to either DCs or macrophages. In contrast, the majority
of MDSC from gp91phox-/- tumor-bearing mice differentiated to F4/80+Gr-1- macrophages
or CD11c+CD11b+ DCs (Fig. 4D).

STAT3 recognizes promoter of NADPH Oxidase subunit.
The STAT3 transcription factor plays a critical role in accumulation of MDSC in
tumor-bearing mice (51, 131); this led us to hypothesize that STAT3 could be involved in
the increased NOX2 levels in MDSC. To assess the role of STAT3 in regulation of
NOX2 we concentrated on one subunit - p47phox. To determine whether STAT3 could
bind the p47phox promoter, a chromatin immunoprecipitation (ChIP) assay was performed
with the 32D myeloid cell line. 32D cells are murine myeloid cells that depend on IL-3
for growth and rapidly undergo apoptosis after IL-3 withdrawal (132). Due to the
requirement for IL-3, these cells constantly have high levels of STAT3 phosphorylation
(133), making them a perfect candidate for this experiment As shown in Fig. 5A, antiSTAT3 antibody precipitated DNA that was amplified by primers specific for the p47phox
promoter region, indicating STAT3 binding to the p47phox promoter. The promoter region
of this gene contains the sequence TTCCCAGAG, which is almost identical to the
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STAT3 binding sequence TTCCCAGAA with the exception of one nucleotide. To verify
that these two sequences had similar binding pattern, embryonic stem (ES) cells were
transfected with a constitutively active STAT3 mutant (STAT3C) (131). Nuclear extract
was prepared and binding of probes containing the consensus STAT3 binding sequence
and p47phox promoter-derived sequence was assessed by EMSA. Both probes showed the
same pattern of binding. Importantly, binding of the p47phox-derived probe was
completely blocked by non-labeled probe containing the STAT3 consensus sequence
(Fig. 5B).

Stat3 activity regulates expression of NADPH Oxidase
To investigate the requirement of STAT3 for ROS production and p47phox
expression in MDSC, we used mice with a targeted disruption of STAT3 in myeloid cells
STAT3 mutant mice (STAT3MT) were generated as described previously (134). Briefly,
mice in which the STAT3 gene is flanked by two loxP sites were crossed to a mouse in
which the cre cDNA is inserted into the mouse lysozyme M gene by a knockin approach.
Lysozyme M is exclusively expressed in cells of the monocyte/macrophage and
granulocyte lineages of hematopoietic differentiation; disruption of the STAT3 gene was
therefore expected to take place only in these cell types. The ensuing STAT3 mutant
protein lacks amino acids 701-732, including the tyrosine and serine residues critical for
STAT activation.
EL-4 tumors were established in STAT3MT or their wild-type littermates (WT).
Since lack of STAT3 prevented the development of MDSC (51 and data not shown) we
evaluated the effect of STAT3 disruption of NOX2 in CD11b+ macrophages. Peritoneal
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macrophages were induced by injection of thioglycollate and collected 3 days posttreatment. Cells were labeled with anti-CD11b antibody and their ability to generate ROS
was analyzed. Both spontaneous and PMA-inducible levels of ROS in STAT3MT CD11b+
cells were substantially lower than that in their wild-type counterparts (Fig. 6A). CD11b+
macrophages were isolated from the peritoneum of tumor-free and tumor-bearing WT or
STAT3MT mice and the expression of gp91phox and p47phox evaluated by qRT-PCR.
Disruption of STAT3 resulted in significant reduction in the expression of gp91phox and
p47phox gene (Fig. 6B) and p47phox protein (Fig. 6C). We then assessed the effect of overexpression of STAT3 on NOX2 by analyzing NOX2 mRNA in STAT3C-transfected ES
cells (135). Normally, ES cells cultured in the presence of leukemia inhibitory factor
(LIF) display functionally active phospho-STAT3. LIF withdrawal leads to a substantial
decrease in pY705STAT3 within 48 hr (40). Over-expression of STAT3C in ES cells
prevented downregulation of pY-STAT3 and resulted in a substantial increase in the
expression of gp91phox and p47phox (Fig. 6D). Taken together, these data indicate that
STAT3 directly regulates NOX2 expression and ROS production in myeloid cells.
Additionally, we used the STAT3 inhibitor JSI-124 (25) to block STAT3 activity
in MDSC in vitro and compare its effects on ROS generation. JSI-124 is a plant natural
product identified previously as cucurbitacin I, a member of the cucurbitacin family of
compounds that are isolated from various plant families such as the Cucurbitaceae and
Cruciferae and have been used as folk medicines for centuries in countries such as China
and India. JSI-124 reduced the levels of phosphotyrosine STAT3 and tyrosine
phosphorylation of its upstream activator JAK2 without affecting total protein levels in
many human cancer cell lines including pancreatic, lung, and breast carcinomasand. The
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high selectivity of JSI-124 for disrupting STAT3 signaling is demonstrated by the fact
that in human tumor cell lines, neither the PI3k/Akt, Ras/Raf/MEK/ERK, or the JNK
signaling pathways are affected by JSI (Blaskovich 2003). Our lab independently showed
that JSI-124 down-regulates STAT3 phosphorylation in MDSC without affecting
phosphorylation of other STAT family members. Treatment of tumor-bearing mice with
JSI-124 reduced the presence in of MDSC in spleens (137). MDSC were isolated from
spleens of 3-week MC38 tumor-bearing mice and treated with JSI-124 in the presence of
TCCM. Twenty-four hour treatment with the STAT3 inhibitor dramatically reduced the
level of ROS in these cells (Fig 7A). JSI-124 caused a decrease in the expression of
p47phox and gp91phox as early as 6 hr after the start of treatment (Fig. 7B). JSI-124
treatment also resulted in a substantial decrease in the level of p47phox protein in these
cells (Fig. 7C).
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Figure 1. ROS level in MDSC from tumor-bearing mice and cancer patients
A. Spleens from naïve tumor-free and tumor-bearing mice were collected 3 weeks after tumor
injection. Splenocytes were stimulated with PMA and labeled anti-Gr-1 antibody and anti-CD11b
Abs. ROS were measured in Gr-1+CD11b+ cells by labeling cells with the oxidation-sensitive dye
DCFDA as described in Materials & Methods. Each group included 4 mice. Avg. and std. dev. of
the mean fluorescence intensity (MFI) are shown. B. H2O2 production by spleen MDSC from CT26 or EL-4 tumor-bearing mice. H2O2 was measured as described in Materials & Methods. C.
Splenocytes from EL-4 tumor-bearing and naive C57BL/6 mice were loaded with 2 mM DCFDA
and cultured at 37°C for 30 min in RPMI 1640 in the presence of either ionomycin (2 µM) or
LPS (1 µg/ml). ROS level was measured within the population of Gr-1+CD11b+ cells. D. ROS
generation by MDSC from spleens of CT26, EL-4, and MC38 tumor-bearing mice were
evaluated at different time points after tumor injection.
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Figure 2. ROS production in MDSC from patients with head and neck cancer.
Peripheral blood MNC from healthy donors and patients with HNC were labeled with a cocktail
of anti-CD11b, anti-CD14 and anti-CD33-specific antibodies and stained with DCFDA to detect
ROS level within the population of CD11b+CD14-CD33+ cells. A. The gating strategy to identify
MDSC. CD14-CD11b+ cells were gated first followed by gating of CD33+ cells. Histograms show
representative fluorescence intensities of DCFDA in CD14-CD11b+CD33+ MDSC from patients
and donors before and after PMA stimulation. B. Summarized data obtained from 5 patients and 5
healthy donors. *-statistically significant difference (p<0.05)
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Figure 3. Up-regulation of NADPH Oxidase in MDSC
A. Gr-1+ cells were isolated from spleens of naïve or CT-26 tumor-bearing mice. RNA was
extracted and expression of NADPH oxidase subunits was measured in triplicates by qRT-PCR.
Three experiments with the same results were performed. *-statistically significant difference
(p<0.05) between control and tumor-bearing mice. B. MDSC from spleens of CT26, EL-4, and
MC38 tumor-bearing mice were evaluated at different time points after tumor injection. Gr1+CD11b+ cells were isolated on weeks 2 and 3 after injection of tumor cells and the expression of
gp91phox and p47phox was measured by qRT-PCR. Each experiment was performed in triplicates
and each group included 3 mice. C,D. Protein levels of gp91phox and p47phox were determined in
total cell lysate (C) or membrane fractions (D) of Gr-1+CD11b+ isolated cells indicative of an
elevated activation status when compared to naive counterparts.
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Figure 4. NADPH Oxidase is responsible for ROS production in splenic MDSC and the
antigen-specific suppression of T cells.
A. Production of ROS was evaluated in splenic Gr-1+CD11b+ MDSC from EL-4 tumor-bearing
and gp91phox knockout mice. Each group included 5 mice. *-statistically significant difference
(p<0.05) between wild-type and gp91phox-/- tumor-bearing mice. B, C. MDSC were isolated from
naïve, wild-type, or gp91 KO mice and cultured with 1x105 splenocytes from OT-1 transgenic
mice. IFN-! production was measured in triplicates in ELISPOT assay (B). (C) Proliferation after
stimulation with OVA-derived specific or control peptide (10 µg/ml) was determined. CPM –
counts per minutes. Thymidine uptake in cells stimulated with control peptide was <1000 cpm.
The values obtained from cells stimulated with control peptides were subtracted from values from
cells stimulated with specific peptide. D. Splenic MDSC from wild-type and gp91 KO tumorbearing mice and cultured with 20 ng/ml GM-CSF and 25% v/v TCCM for 5 days. Cell
phenotype was evaluated by flow cytometry. Cumulative results from three performed
experiments are shown.
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Figure 5. STAT3 recognition of NADPH Oxidase subunit promoter .
A, B. Nuclear extracts from STAT3C-transfected ES cells were prepared and used in EMSA. SIE
–conventional STAT3 specific probe, p47phox sequence derived from promoter region of p47phox.
Mutant probe – mutant p47phox derived probe, SIE cold inhibition – binding to p47phox derived
probe in the presence of 50-fold excess of unlabeled SIE probe. B. ChIP assay. DNA from 32D
cells was precipitated with either anti-STAT3 antibody (STAT3) or control rabbit IgG (IgG).
PCR was performed with primers specific for promoter regions of p47phox or !-actin genes (C).
Input – PCR reaction performed with DNA isolated from nuclear extract without precipitation.
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Figure 6. STAT3 regulates expression of NADPH oxidase
A, B, C. EL-4 tumor cells were injected into wild-type (WT) or STAT3-mutant (STAT3MT) mice.
Cells from the peritoneum were flushed out and collected 21 days after injection of EL-4 cells. To
recruit macrophages, thioglycollate was injected i.p. 3 days prior to sacrificing animals.
Peritoneal cells were stained with anti-CD11b antibody and production of ROS was analyzed (A).
CD11b+ macrophages were isolated from peritoneum of WT or STAT3MT mice. The expression
of p47phox was assessed by Real-Time PCR (B) and amount of p47phox protein was determined by
Western blotting (C). D. R1-ES cells were transfected with either control plasmid (R1-C) or
Stat3C plasmid (R1-Stat3C) (18). Expression of gp91phox and p47phox after transfection was
determined.
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Figure 7. Effect of STAT3 inhibitor JSI-124 on ROS level in MDSC
Gr-1+ cells were isolated from spleens of 3-week MC38 tumor-bearing mice. Cells were cultured
with tumor-cell-conditioned medium for 24 hours and treated with the STAT3 inhibitor, JSI-124
(1.5 µM). A. ROS level measured in Gr-1+CD11b+ cells. B. Expression of gp91phox and p47phox at
different time points after treatment with JSI-124. C. Levels of p47phox protein in JSI-124 treated
Gr-1+CD11b+cells were analyzed by Western blotting. Hela cells were used as positive controls
for phosphorylated STAT3
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II. Suppressive Activity and Differentiation of MDSC in the Tumor Site: the Role of
Tumor Hypoxia and HIF-1a.
MDSC have been reported to inhibit T cell activation by manipulating l-arginine
metabolism. The action of the enzymes Arg1 and iNOS, independently or synergistically,
has been reported to inhibit the response of T lymphocytes to antigen. Although
simultaneous activation of both enzymes has been argued to be unfeasible because
activation of one would limit the availability of l-arginine as a substrate for the other, if
we take kinetics into consideration we find that the enzymatic activity of either enzyme
should be greatly affected (138). In fact, the combined activity of ARG and NOS is
important for the suppressive activity of tumor-infiltrating CD11b+ myeloid cells (78)
and of Gr-1+CD11b+ cells isolated from the spleen of mice that are chronically infected
with helminthes (140).
Interestingly, despite large number of MDSC in spleens and lymph nodes of
tumor-bearing mice, and in the peripheral blood of cancer patients with advanced disease,
T cells in these compartments seem to retain the ability to respond to different tumor nonspecific stimuli including viruses, lectins, IL-2, and stimulation with CD3- and CD28specific antibodies (140-143). In a sharp contrast, T cells directly isolated from tumors
display profound defects in their ability to respond to those stimuli (144-146), suggesting
that T cells in the lymphoid organs and in tumor tissues are inhibited by distinct
mechanisms. Based on these observations, we hypothesized that MDSC inside tumor
tissues exploited a suppressive mechanism different that MDSC in peripheral lymphoid
organs. The roles of hypoxia, a prominent feature of tumor tissues, and the transcription
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factor HIF-1! were also evaluated in controlling MDSC activity. We expanded our
studies to the differentiation of MDSC inside the tumor microenvironment and the
possible regulatory role of this phenomenon by hypoxia and HIF-1!.

Phenotype of MDSC in the tumor site
In order to compare MDSC from the tumor site to MDSC from peripheral
lymphoid organs (spleen), we developed a model where EL-4 tumor grows as an ascitis
in C57BL/6 mice. The dose of EL-4 cells was selected to form an ascitis within 3 weeks
after tumor injection. MDSC were sorted based on Gr-1 and CD11b co-expression from
the spleen and tumor of the same mouse (Fig. 8A).
MDSC from both sites expressed the same level of Gr-1 and CD11b molecules
and had similar mixed granulocytic and monocytic cell morphology (Fig. 8B). The
number of total MDSC in the ascitis of our model was on average 3-4 fold lower than in
spleen. Recent studies have determined that MDSC consists of two major subsets: cells
with granulocytic phenotype (CD11b+Ly6G+Ly6Clow) and cells with monocytic
phenotype (CD11b+Ly6G-Ly6Chigh) (20,147). We decided to analyze the morphology of
MDSC from both sites to compare possible differences in MDSC composition. We found
that granulocytic MDSC were the predominant type of MDSC in both sites. Moreover,
the ratio of granulocytic and monocytic MDSC isolated from tumor or spleens was
practically identical (Fig. 8C). The CD11c marker specific for DCs was not expressed on
either spleen or tumor MDSC and almost all cells from both sites expressed the Neu
marker (Fig. 8C). A slightly higher proportion of Gr-1+CD11b+ MDSC from the tumor
site did exhibit low expression of the macrophage marker F4/80 than did MDSC from
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spleens (p=0.06) (Fig. 8C). Thus, MDSC from the tumor and spleen of tumor-bearing
mice had similar morphology and phenotype.

Function of MDSC in the tumor microenvironment.
We proceeded to compare the ability of tumor and spleen MDSC to suppress
antigen-specific T cell activation. Again, we evaluated two basic functions of T cells:
IFN-! production and T-cell proliferation. The antigen-specific response to MHC class Irestricted SIYRYYGL (SIY) peptide was measured in 2C transgenic CD8+ T cells.
MDSC were isolated from the tumor site and spleens of the same mice and used under
the same experimental conditions; Gr-1+CD11b+ immature myeloid cells (IMC) from
spleens of naïve tumor-free mice were used as a control. As was demonstrated in
previous studies, IMC lack immunosuppressive activity (53,78,148,149) In contrast, both
spleen and tumor MDSC effectively suppressed the antigen-specific T-cell response,
though the level of suppression was significantly (p<0.05) higher in tumor MDSC (Fig.
9A). We also evaluated the T cell response after activation with anti-CD3/CD28
antibodies. Under this scenario, spleen MDSC did not suppress the T-cell response,
whereas tumor MDSC exerted a profound suppressive effect (Fig. 9B).
A similar effect was observed in a spontaneous lung cancer model. The
mCC10TAg transgene was made by fusing the coding sequences of the SV40 TAg
oncogene with the mCC10 promoter (150), a promoter that targets expression of the
transgene only to proximal pulmonary lung epithelial cells. Under this model, mice
develop multifocal pulmonary adenocarcinoma in the lung at three months of age. MDSC
were isolated from tumor or spleens of the three-month-old mice and then added to
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responder cells from naïve mice stimulated with anti-CD3/CD28 antibodies. Tumor
MDSC showed a marked suppressive activity, whereas spleen MDSC failed to suppress
non-specific T-cell proliferation (Fig. 9C). Thus, MDSC from the tumor site and spleen
of the same mouse exhibit a marked difference in their ability to suppress T-cell function.

Manipulation of L-arginine metabolism as the suppressive mechanism employed by
Tumor-MDSC
Although recently MDSC have been attributed with multiple novel suppressive
methods, the traditional factors implicated in MDSC-mediated immunosuppression
consisted of ROS and manipulation of l-arginine (151,152). We first evaluated ROS
levels within the population of MDSC from spleen and tumors. IMC from spleen of naïve
mice served as controls. As shown in the previous section, MDSC from spleens of tumorbearing mice displayed a significantly higher level of ROS than the cells from tumor-free
mice. Surprisingly, ROS production in tumor MDSC was significantly lower than that of
splenic MDSC (Fig. 10A). Expression of gp91phox and p47phox components of NOX2 were
also significantly lower in MDSC isolated from the tumor site than that in MDSC from
the spleen (Fig. 10B). In contrast, MDSC isolated from the tumor site displayed lofty
arginase activity and high expression of arg1 than spleen MDSC from the same mice
(Fig. 10C). In addition, large amounts of NO were detected in cultures of MDSC and
splenocytes. The expression of iNOS was >10-fold higher in MDSC from the tumor site
after stimulation with IFN-y (Fig. 10D).
To determine if ROS played any role in the suppressive activity of tumor MDSC,
we performed experiments with gp91phox-/- tumor-bearing mice. Lack of ROS eliminated
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inhibitory potential of spleen MDSC but the suppressive potential of tumor MDSC was
not affected (Fig. 10E). In the other hand, inhibition of iNOS with LMMA, and arg1 with
nor-NOHA, completely abrogated suppressive activity of tumor-derived MDSC (Fig.
10F). From these experiments we concluded that MDSC from the tumor use arginase and
NO to suppress T-cell function, whereas splenic MDSC primarily utilize the ROSmediated mechanism.

MDSC in Tumor Tissues of Cancer Patients.
Our data indicated that MDSC from the tumor site and peripheral lymphoid
organs of tumor-bearing mice differed in their ability to produce ROS and NO. To test
whether a similar phenomenon is observed in cancer patients, we studied paired samples
of peripheral blood and tumor tissues obtained from patients with head and neck cancer.
MDSC were defined as CD14-CD11b+CD33+ cells (Fig. 11A). ROS and inos were
measured in MDSC using flow cytometry. MDSC in the tumor had significantly lower
ROS production than MDSC in peripheral blood (Fig. 11B). In contrast, inos levels in
tumor MDSC were substantially higher than in blood MDSC (Fig. 11C). Thus, these
results, which are similar to those observed in tumor-bearing mice, suggest that
differences in MDSC may represent general phenomenon.

Effect of tumor microenvironment on MDSC function and differentiation
MDSC are a heterogeneous group of cells. Therefore, despite similarities in the
morphology and phenotype of MDSC isolated from tumor sites and spleens, it was
difficult for us to formally exclude the possibility that MDSC in different sites may
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represent different populations of myeloid cells (i.e. TAMs). To address this question as
well as to identify the mechanisms of MDSC function in the tumor site, we performed a
direct transfer of Gr-1+CD11b+ MDSC isolated from spleens of EL-4 tumor-bearing
congenic (CD45.1+) mice into the ascitis of EL-4 tumor-bearing C57BL/6 (CD45.2+)
recipients. EL-4 cells, a lymphoma cell lime, express CD45.2 but not the CD45.1 marker
(data not shown). This system allowed for discrimination between tumor cells and
MDSC. In parallel, MDSC were injected i.v. into either EL-4 tumor-bearing or tumorfree recipients to evaluate donor cells in the spleen. Donor cells isolated from spleens 4 hr
after the transfer retained their significant (p<0.01) ability to suppress antigen-specific Tcell responses (Fig. 12A). However, these cells failed to inhibit the T cell response to aCD3/CD28 stimulation (Fig. 12B). In contrast, donor cells isolated from tumor site 4 hr
after the transfer exhibited strong suppressive activity of both antigen-specific and nonantigenic T cell response (Fig. 12A,B). The expression of arg1 and inos in donor cells
isolated from tumors was significantly higher; simultaneously p47phox mRNA was
significantly lower than donor cells in spleens (Fig. 12C). At longer time points, 18 hr
after post transfer to be specific, donor cells isolated from tumor sites gained dramatic
suppressive activity (Fig. 12D) , their expression levels of arg1 and inos elevated (Fig.
12E), and their ability to generate ROS was diminished (Fig. 12F). Thus, substantial
changes in MDSC suppressive activity and up-regulation of inos and arg1 were observed
as early as 4 hr after adoptive transfer of MDSC into the tumor site.
It is known that MDSC can differentiate into mature myeloid cells. We therefore
investigated the fate of these cells after transfer into the tumor site and donor cells that
reached the spleen. CD45.1+ MDSC isolated from spleens of tumor-bearing mice were

50

transferred i.v. or injected directly into ascitis of CD45.2+ recipients. No differences were
observed in the phenotype of cells isolated 4 hr after the transfer (data not shown).
Eighteen hour post transfer most of the donor MDSC (>70%) in the spleen and tumor site
still retained the MDSC phenotype (Gr-1+CD11b+) (Fig. 13A). Donor cells that lost Gr-1
expression were represented in the spleens primarily as CD11c+ DCs, whereas in the
tumor site as F4/80+ macrophages. After 48 hr, the proportion of Gr-1+CD11b+ MDSC
among donor cells in spleens remained about the same (> 60%). However, in the tumor
site it was substantially decreased with less than 30% of donor cells retaining the
phenotype of MDSC (Fig. 13B). Practically all Gr-1 negative donor cells in the tumor
site, but only less than 30% of cells in the spleen, were F4/80+CD11b+ macrophages. In
contrast, few Gr-1- cells in the tumor site express the CD11c marker of DCs, whereas in
spleen more than 30% of these cells were CD11c+ (Fig. 13B). Three days after the
transfer, all Gr-1 negative donor cells in the tumor site remained F4/80+CD11b+
macrophages, whereas macrophages represented less than 20% of these cells in spleen
(Fig. 13C). No CD11c+ donor cells were detectable in spleens, which may reflect the
possible migration of DCs out of the spleen. Thus, in the tumor microenvironment,
MDSC rapidly differentiated into F4/80+CD11b+ TAM. In contrast, MDSC in spleens
remained undifferentiated much longer and differentiated equally to macrophages and
DCs.

Effect of Hypoxia in MDSC function and differentiation.
Our data demonstrates that the tumor microenvironment rapidly changes the
function of MDSC and promotes their differentiation to TAM. We investigated the
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possible mechanism of this effect. Hypoxia is one of the major characteristics of the
tumor microenvironment and we decided to test the effect of hypoxia on MDSC. We
incubated MDSC isolated from spleens of tumor-bearing mice in complete culture
medium and GM-CSF at normoxic or hypoxic (1% O2) conditions for 48 hr. Hypoxia
significantly (p<0.05) reduced the expression of gp91phox and p47phox components of
NOX2 (Fig. 14A), which resulted in a substantial decrease in the level of ROS production
in these cells (Fig. 14B). In contrast, MDSC subjugated to hypoxia had elevated
expression of arg1 and inos (Fig. 14C). MDSC cultured in hypoxia acquired the ability to
suppress T-cell activation in response to anti-CD3/CD28 antibody (Fig. 14D). Thus,
hypoxia recapitulated the effect of the tumor microenvironment on MDSC function.
To assess the effect of hypoxia on MDSC differentiation, Gr-1+CD11b+ cells from
spleens of tumor-bearing mice were cultured for 5 days in normoxia or hypoxia in the
presence of GMCSF. We observed accumulation of cells with macrophage morphology
in the hypoxic group (Fig. 15A). In hypoxia, the proportion of Gr-1+CD11b+ MDSC was
4-fold lower compared with cells cultured at normoxia (p<0.01), whereas the proportion
Gr-1-CD11b+F4/80+ M! was significantly higher (p<0.05) (Fig. 15B). In contrast, the
proportion of CD11c+ cells was significantly (p<0.05) higher among the cells cultured at
normoxia than those incubated at hypoxia (Fig. 15B). Thus, these data indicate that
hypoxia can indeed promote the differentiation of MDSC to macrophages, similar to the
effect observed in the tumor microenvironment.
We then asked whether hypoxia could cause functional polarization of
macrophages during their differentiation from MDSC. MDSC isolated from spleens of
tumor-bearing mice were cultured at normoxia and hypoxia for 5 days, followed by
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isolation of F4/80+ cells and evaluation of their cytokine gene expression. As controls, we
used F4/80+ macrophages obtained from peritoneal cavities of naïve mice and F4/80+
cells collected from the ascitis of tumor-bearing mice.
As expected, TAM expressed substantially higher levels of M1 markers Arg1 and
Il-10 than control peritoneal macrophages (Fig. 15C,E). Unexpectedly, in our experiment
TAM also expressed higher levels of M2 markers iNOS and Il-12 than control peritoneal
M! (Fig 15D,F). The expression of TGF-! and Il-6 were very similar between the two
groups (Fig 15G,H). Based on cytokine expression, macrophages generated from MDSC
under hypoxic conditions very much resembled macrophages isolated directly from the
tumor as they also expressed higher levels of Il-10, arg1, inos, Il-12, and Il-6 than
macrophages generated under normoxic conditions. TGF-" levels were very similar in
M! generated in vitro under either condition. These results suggest that hypoxia drives
the differentiation of MDSC to a similar phenotype expressed by macrophages inside
tumor tissues. The fact that in our experimental model TAM expressed cytokines
associated with both M1 and M2 polarization states may indicate the need for revision of
the notion that TAM are strictly M2-polarized macrophages.

Requirement of HIF-1# for tumor microenvironment- and hypoxia- induced
changes in MDSC
Up-regulation of HIF-1! is one of the major effects of hypoxia. We investigated
the possible role of HIF-1! in the regulation of MDSC differentiation and function.
Shortly after exposing splenic MDSC to hypoxia, we observed accumulation of HIF-1!
(Fig. 16A). To test the possible role of this transcription factor on MDSC function in
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vitro we used deferoxamine (DFO), a compound that stabilizes HIF-1!. Spleen MDSC
from tumor-bearing mice were treated with DFO for 48 hr, washed and then added to
splenocytes stimulated with anti-CD3/CD28 antibodies. Untreated MDSC did not
suppress proliferation (Fig. 16B) or IFN-" production (Fig. 16C) from activated T-cells .
However, MDSC pre-treated with DFO caused profound suppression of T-cell function
(Fig. 16B,C). Similar to the effects observed after treatment with hypoxia, DFO caused
significant up-regulation of the expression of arg1, inos and a decrease in the expression
of NOX components p47phox and gp91phox (Fig. 16D,E). It also promoted macrophage
differentiation from MDSC during a 5-day culture with GM-CSF (Fig. 16F). Taken
together, these results suggested that HIF-1! could be responsible for the observed effect
of the tumor microenvironment on these cells.
To directly address this possibility, we used mice with conditional HIF-1!
deletion. HIF-1! flox mice were crossed with Mx-Cre mice and HIF-1! deletion was
induced by repeated poly:IC administration (Fig. 17A). Poly:IC is a strong inducer of
type I IFN and it could potentially affect MDSC function. Therefore, to exclude this
possibility and to make sure that HIF-1! deletion is confined only to hematopoietic cells,
we decided to reconstitute the bone marrow (BM) of wild-type recipients with HIF-1a
deficient progenitors. BM cells (2x106) from CD45.2+ HIF-1!-deficient (HIF1!floxCre+/-) or control (HIF-1!floxCre-/-) mice were used to reconstitute lethally
irradiated CD45.1+ congeneic naïve mice. The BM progenitors from HIF-1!-deficient
and wild-type mice showed similar engraftment potential (Fig. 17B). We allowed two
weeks for the myeloid compartment to repopulate in recipients. After two weeks we
established s.c. tumors with EL-4 cells; no significant differences in tumor growth
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between the groups were seen (data not shown). At the time of submission of this
manuscript, generation of HIF-1a-/- animals was still ongoing. Due to the insufficient
number of mice we cannot provide statistical significance in our results; consequently, it
is important to disclose that the accompanying results should at this stage be regarded as
preliminary rather than final.
We evaluated the populations of myeloid cells 3 weeks after tumor injection (1.5
cm in diameter). Large expansion of Gr-1+CD11b+ MDSC was observed in the spleen of
tumor-bearing mice that received HIF-1!+/+ BM. Surprisingly, only a modest increase of
MDSC was observed in recipients of HIF-1!-deficient BM (Fig. 17C). The proportion
and absolute number of MDSC in the spleen of mice reconstituted with HIF-1!-deficient
BM was significantly (p<0.01) smaller than in mice reconstituted with HIF-1!+/+ BM
(Fig. 17C). No significant differences were found in the proportion of macrophages and
DCs between the tumor-bearing recipients of HIF-1!-deficient and wild-type BM cells
(Fig. 17C). The level of ROS was evaluated within the population of spleen MDSC. The
HIF-1!-deficient MDSC from tumor-bearing mice generated larger amounts of ROS than
wild-type counterparts (Fig. 17D).
To assess the effect of the tumor microenvironment on HIF-1!-deficient MDSC,
Gr-1+CD11b+ cells were isolated from spleens of tumor-bearing mice reconstituted with
HIF-1!-deficient or wild-type BM and then injected directly into the ascitis of CD45.1+
congenic mice. Twelve hours later, Gr-1+CD45.2+ donor MDSC were isolated and used
in experiments. Similar to previous experiments, donor MDSC with wild-type HIF-1!
showed profound suppressive activity against T cells stimulated with anti-CD3/CD28
antibodies (Fig. 18A). The expression of arg1 and inos in donor HIF-1! positive MDSC
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was dramatically up-regulated after transfer into the tumor site (Fig. 18B). The
suppressive effect of HIF-1!-deficient donor MDSC, as well as the expression of arg1
and inos in these cells, was significantly (p<0.01) lower (Fig. 18A,B). The opposite effect
was observed in the levels of ROS as HIF-1!-deficient donor MDSC had substantially
higher ROS production than their wild-type counterparts (Fig. 18C).
We then evaluated the differentiation of donor cells in the tumor
microenvironment. We gated on CD45.2+CD11b+ cells; gating of CD11b+ cells was
necessary to exclude CD45.2 EL-4 tumor cells from the analysis. Within 12 hr after the
transfer of either wild-type or HIF-1!-deficient MDSC, about 30% of donor
(CD45.2+CD11b+) cells lost the expression of Gr-1 (data not shown). Most (>60%) of the
HIF-1!-deficient Gr-1- donor cells acquired the CD11c marker, suggesting that these
cells differentiated towards DCs, whereas CD11c was practically not expressed on wildtype donor cells. The opposite effect was observed in the expression of F4/80 (Fig. 18D).
The proportion of F4/80+ TAM among HIF-1!-deficient donor cells was two-fold lower
than that among wild-type donor cells.
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Figure 8. Phenotype of MDSC in tumor site.
A-C. EL-4 tumor cells (3x105) were injected i.p. into C57BL/6 mice. After three weeks, spleens
and cells from tumor ascitis were collected. Gr-1+CD11b+ MDSC were sorted (A) and their
morphology was evaluated by staining with H&E (B) (maginification x 200). C. Analysis of
surface markers in gated Gr-1+CD11b+ MDSC isolated from splenic and tumors of the same mice.
Three individual experiments were performed.
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Figure 9. Function of MDSC in tumor site.
A,B. Gr-1+CD11b+ cells purified from spleens of tumor-free mice (naïve), or spleens (SPL) and
ascitis (ASC) of EL-4 tumor-bearing mice were cultured at indicated ratios with 105 splenocytes
from transgenic 2C mice. A. Splenocytes were stimulated with control and specific peptides and
IFN-! production was measured in ELISPOT assay. Number of spots per 105 2C splenocytes is
shown. Values in cells stimulated with control peptide were subtracted. * - statistically significant
(p<0.05) difference from naïve mice. B. Splenocytes were stimulated with anti-CD3/CD28
antibodies and splenocyte proliferation was evaluated using 3H-thymidine uptake. All
experiments were performed in triplicates. A typical result of three performed experiments

is shown. C. Splenocytes were labeled with CFSE (1µM) and cultured with MDSC
isolated from spleens and lungs of mCC10Tg tumor-bearing mice. Splenocytes were
stimulated with anti-CD3/CD28 antibodies and proliferation was measured by CFSE
dilution. Three experiments with similar results were performed.
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Figure 10. Factors regulating MDSC suppressive activity.
A. Cells collected from the tumor site or spleens of EL-4 tumor-bearing mice were stimulated
with PMA and labeled with 1µM DCFDA. DCFDA fluorescence was measured in Gr-1+CD11b+
population. Each group included 4 mice. * - statistically significant difference (p<0.05) from
naïve mice. B. Expression of gp91phox and p47phox was measured Gr-1+CD11b+ cells isolated
from spleens or tumor of the same mice. C. Arg 1 gene expression and enzymatic activity were
evaluated in MDSC from tumor site and spleen. All experiments were performed in triplicates
and repeated three times. * - statistically significant differences (p<0.05) from naïve mice; # statistically significant differences between ascitis and spleen of the same mice. D. MDSC from
spleen and tumor ascitis were stimulated with IFN-! (30 ng/mL) for 48 hr and expression of iNOS
was measured. The same cells were mixed at the indicated ratio with 2x105 splenocytes
stimulated with anti-CD3/CD28 antibodies. After 48 hr incubation culture medium was collected
and assayed for nitrites. Experiments were performed in triplicates and repeated three times with
similar results. E. Suppressive activity of MDSC from gp91phox ko mice on IFN-! production by
transgenic 2C T cells after stimulation with either specific peptide or with anti-CD3/CD28
antibodies. * - statistically significant differences (p<0.05) from naïve mice. F. MDSC isolated
from spleens or tumor site were incubated at a 1:4 ratio with naive syngeneic splenocytes
stimulated with anti-CD3/CD28 antibodies in the presence of iNOS (0.5 mM L-NNMA) and
arginase (0.5 mM nor-NOHA) inhibitors. IFN-! production and cell proliferation were measured.
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Figure 11. MDSC in peripheral blood and tumor tissues of cancer patients.
Peripheral blood and tumor tissues were collected from patients with HNC during surgical
resection. A. A typical example of gating of CD11b+CD14+CD33+ MDSC from the same patient
in flow cytometry. B. Cells were stained with DCFDA to detect ROS level within the population
of CD11b+CD14+CD33+ cells from the same patient. Top panel – typical example of DCFDA
staining in these cells; bottom panel – cumulative results from six patients. ** - statistically
significant difference between MDSC in the tumor site and peripheral blood. C. Cells were
labeled with anti-iNOS antibody and the protein level was measured within the population of
CD11b+CD14+CD33+ cells. Top panel – typical example of iNOS staining of one patient. Bottom
panel – cumulative results from six patients.* - statistically significant difference between MDSC
in the tumor site and peripheral blood.
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Figure 12. Effect of the tumor microenvironment on MDSC function.
MDSC isolated from spleens of congenic CD45.1+ mice bearing 3 week s.c. EL-4 tumor were
transferred into ascitis of CD45.2+ EL-4 tumor-bearing recipients. CD45.1+ donor cells were
recovered using magnetic beads 4 hr after cell transfer. For controls, CD45.1+ MDSC were
transferred i.v. into EL-4 tumor-bearing recipients or naive recipients and recovered from spleens
4 hrs after cell transfer. A. After adoptive transfer, CD45.1+ MDSC were cultured with 2C spleen
responder cells (Resp.) (1:4 ratio) stimulated with control and specific peptides. IFN-! production
was measured by ELISPOT assay. Each experiment was performed in triplicates and repeated
twice. B. Similar experiments performed using stimulation with anti-CD3/CD28 antibodies. C.
Evaluation of gene expression of argI, iNOS, and p47phox in MDSC post-adoptive transfer. Each
experiment was performed in triplicates and repeated twice with the same results. D-F MDSC
after 18h adoptive transfer. D. Proliferation of 2C splenocytes in the presence of MDSC
(MDSC:splenocyte ratio 1:4) in response to stimulation with specific peptide or with antiCD3/CD28 antibodies. Each experiment was performed in triplicates and repeated twice. Cell

proliferation without peptide was below 1000 CPM. E. Expression of NOX subunits,
argI and inos. F. ROS assessment in Gr-1+CD11b+ cells before and after adoptive
transfer. MFI for one typical experiment is shown.
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Figure 13. Differentiation of MDSC in the tumor microenvieonment
Phenotype of donor CD45.1+ cells at different times after adoptive transfer. A. 18h post
adoptive transfer. B. 48h post adoptive transfer. C.72h post adoptive transfer.
Macrophages: F4/80+CD11b+Gr-1-; Dendritic cells CD11c+CD11b+Gr-1-.
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Figure 14. Regulation of MDSC function by hypoxia.
MDSC were isolated from spleens of CT26 tumor-bearing mice and cultured in medium
containing 10 ng/ml GM-CSF and 25% CT26 TCCM under normoxic and hypoxic (1% O2)
conditions using a hypoxic chamber. A. Expression of NOX subunits was evaluated in triplicates
after 2 days. B. Cells were collected after 3 days of culture and DCFDA intensity was measured
within the Gr-1+CD11b+ population. Typical result of three performed experiments is shown. C.
Expression of argI and inos was evaluated in MDSC after 24 hr and 48 hr incubation. D. MDSC
were cultured for 48 hr under normoxic or hypoxic conditions and their ability to suppress
proliferation of anti-CD3/CD28 stimulated splenocytes was evaluated
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FIGURE 15. Regulation of MDSC differentiation by hypoxia
A. MDSC were cultured for 5 days with GM-CSF (10 ng/ml) and 25% TCCM in normoxia or
hypoxia, then fixed and stained with H&E. Magnification x 400. B. Phenotype of MDSC cultured
for 5 days in hypoxia or normoxia. The proportion of cells with indicated phenotype were
evaluated by flow cytometry. Cumulative results of 4 performed experiments are shown. * statistical significant differences (p<0.05) between the groups. C-H. MDSC F4/80+ cells were
isolated from MDSC cultured for 5 days and the expression of cytokines associated with M1 and
M2 M! phenotypes (C. arginase; D. iNOS; E. IL-10; F. IL-12; G. TGF-b; H. IL-6) were
determined by real-time PCR. Results were compared to TAM isolated from tumor-bearing mice
and peritoneal M! from naïve mice.
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Figure 16. Consequences of HIF-1! stabilization in MDSC properties.
A. MDSC isolated from spleens of EL-4 tumor-bearing mice were cultured with GM-CSF (10
ng/mL) in hypoxia for 4 hr or 16 hr. The level of HIF1-! was measured by Western blot. B-F.
MDSC were treated with various concentrations of HIF-1! stabilizer DFO for 48 hr, then washed
and used in the experiments. No effect of DFO on MDSC cell viability was observed at these
concentrations (data not shown). B, C. Effect of DFO-treated MDSC on proliferation (B) and
IFN-" production (C) of splenocytes stimulated with anti-CD3/CD28 antibodies. D, E.
Expression of arg1, inos, gp91phox, and p47phox in DFO-treated MDSC for 48 hr treatment.
Experiments were performed in triplicates and repeated two times with the same results. F.
Percentage of F4/80+CD11b+ M# differentiated from MDSC treated with DFO for 5 days.
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Figure 17. Evaluation of HIF-1!-deficient chimeric mice before and after tumor
establishment.
A. Expression of HIF-1! in HIF-1!fl/flCre+/- and HIF-1!fl/flCre-/- mice after treatment with poly I:C
using real-time PCR. Experiments were performed in triplicates in three mice. B. Reconstitution
of lethally irradiated CD45.1+ congenic mice with CD45.2+ bone marrow from HIF-1! deficient
(HIF-1!flox/flox,Cre+/-) or wild-type (HIF-1!flox/flox, Cre-/-) mice. Blood of mice 2 weeks after bone
marrow transfer was tested. C. CD45.1+ lethally irradiated recipients were reconstituted with
CD45.2+ bone marrow cells from HIF-1!-deficient (-/-) or wild-type (+/+) mice. Two weeks later
mice were inoculated s.c. with 5x105 EL-4 tumor cells. Three weeks after that, spleens were
collected and cell phenotype was evaluated. For control, tumor-free recipients were used. Each
group included three mice. Proportion and absolute number of MDSC (C), * -statistically
significant (p<0.05) differences between mice reconstituted with HIF-1!-/- and HIF- 1!+/+ bone
marrow. D. Splenocytes from tumor-free or EL4 tumor-bearing animals were labeled with
DCFDA and fluorescence determined in the Gr-1+CD11b+ population.
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Figure 18. Changes in MDSC function and differentiation induced by the tumor
microenvironment require HIF-1!. CD45.1+ lethally irradiated recipients were reconstituted
with bone marrow cells from HIF-1! knockout (KO) or wild-type (WT) CD45.2+ mice. Two
weeks later mice were inoculated s.c. with 5x105 EL-4 tumor cells. Three weeks after that
CD45.2+ HIF-1! WT or KO MDSC were isolated from spleens of tumor-bearing mice and then
transferred into ascitis of congenic CD45.1+ mice. Twelve hours later, CD45.2+ CD11b+ donor
cells were isolated and used in the following experiments. A. The MDSC were cultured with antiCD3/CD28 antibody-activated T cells (responder cells, Resp.) and their proliferation was
measured. B. Expression of arg1 and inos was analyzed in the MDSC before and after adoptive
transfer into the tumor milieu. Experiments were performed in triplicates. Each group includes 3
mice. * - statistically significant (p<0.05) differences between the groups. C. ROS in MDSC after
the adoptive transfer was determined with DCFDA. D. Percentage of macrophages and DCs in
the population of CD11b+Gr-1-CD45.2+ donor cells 12 hr post-adoptive transfer.
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Figure 19. Schematic of MDSC function and differentiation in tumor-bearing host.
In lymphoid organs, MDSC retain a high level of NOX2 and increased ROS levels. This is
associated with a little increase in NO production and arginase I activity. As a result these MDSC
produce peroxynitrite and exert their effect only via close cell-cell contact with activated antigenspecific T-cells, which induce antigen-specific T-cell tolerance. At the same time, these MDSC
fail to suppress antigen non-specific activation of T cells. In contrast, at the tumor site, MDSC
due to the effect of hypoxia via HIF-1!, dramatically up-regulate expression of inos and argI,
which is associated with down-regulation of both NOX2 expression and ROS production.
Because of these changes, MDSC acquire the ability to suppress antigen non-specific T cell
functions, which contribute to the profound immune suppression observed within the tumor
microenvironment. In addition, hypoxia via HIF-1! promotes differentiation of MDSC to
immune suppressive TAM that further support the immune suppressive network.
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DISCUSSION

Existing evidence indicates that T lymphocytes in tumor-bearing hosts are
exposed to multiple suppressive factors. T lymphocytes isolated from tumor tissues
display a profound deficiency in their ability to respond to mitogenic stimulation and
their effector functions are severely compromised. As example, T lymphocytes
infiltrating rat gliomas displayed reduced CD3e and TCR expression compared to spleen
cells When TILs were purified and stimulated with polyclonal mitogens ConA or antiCD3 in vitro, their proliferate capacity was markedly diminished compared to spleen T
cells [153]. In contrast, T cells isolated from peripheral lymphoid organs seem to
experience antigen specific anergy to tumor-associated antigens. Circulating CD8+ T
cells, specific for melanoma-associated antigens, were unable to lyse melanoma target
cells or produce cytokines while having capability to lyse Epstein-Barr virus-pulsed
target cells or generate allogeneic responses [146]. Anti-CD3 antibody or PHA-induced
T-cell responses were not affected in patients with metastatic kidney cancer (142). One
possible explanation for these differences is that the tumor microenvironment contains a
large number of different suppressive factors that are not present in the periphery (154).
MDSC are a heterogeneous population of myeloid cells comprised of cells at
various stages of differentiation. They prevent the activation and functionality of T
lymphocytes, limiting the success of immunotherapy strategies aimed to eradicate
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developing cancer cells. The suppression of lymphocytes caused by MDSC has been
demonstrated by numerous laboratories. Elimination of MDSC improves the function of
T lymphocytes to immunotherapeutic treatments and promoting regression of developing
tumors in animal models (139,141,155).
This work demonstrates a dual role played by MDSC in immune suppression in
cancer depending on their location. In lymphoid organs, MDSC retain a high level of
NOX2 and increased ROS levels. This is associated with a little increase in NO
production and Arg I activity. The important role of ROS in spleen MDSC-mediated
suppression of T cells is supported by ample evidence provided during recent years.
(10,19,156-159). ROS was specifically implicated in antigen-specific T cell tolerance
mediated by MDSC (10,159). Due to high generation of ROS, MDSC produce
peroxynitrite and exert their effect only via close cell-cell contact with activated antigenspecific T-cells, which induce antigen-specific T-cell tolerance (10). At the same time,
these MDSC fail to suppress antigen non-specific activation of T cells. The up-regulation
of ROS in MDSC is a common phenomenon observed in a variety of different tumor
models (Figure 1A). Importantly, this phenomenon was observed in human MDSC as
well (Figure 2).
We tried to clarify the reason for the increase in ROS levels in these cells.
Although cells can employ multiple mechanisms for ROS generation, in leukocytes the
primary producer of ROS is NADPH oxidase (NOX2). NOX2 catalyzes the one-electron
reduction of oxygen to superoxide anion using electrons supplied by NADPH. The
importance of this enzyme can be observed in the severity of hereditary chronic
granulomatous disease (CGD). CGD is caused by mutations in any of the genes that
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encode the subunits of the oxidase and patients with CGD experience frequent lifethreatening infections during their lifetime (130). In leukocytes, increased ROS
production in response to different stimuli is regulated primarily by activation of NOX2
via assembly of the enzymatic complex on the cellular membrane after translocation from
the cytoplasm. The response usually does not involve transcriptional regulation of
subunits of the NADPH complex. However, our data demonstrate that in MDSC from
tumor-bearing mice, the substantial increase in the expression of several NOX2 subunits
contributes to the up-regulation of NOX2 activity and ROS production.
Under the scenario of increased expression of NOX2 subunits, we believe that
even slight stimulation of MDSC would result in a substantial production of ROS. An
example of such stimuli could be an interaction of MDSC with activated T cells,
endothelial cells, or fibroblasts in tissues. Under normal conditions, in the absence of
injury, contact of myeloid cells with surrounding cells through adhesion molecules would
result in a modest up-regulation of ROS (160). However, in a situation when NOX2
expression is up-regulated in MDSC, the same interaction results in dramatic increase in
ROS production in these cells. This may explain a previous report that direct cell-cell
contact with antigen-specific CD8+ T cells caused substantially higher level of ROS in
MDSC than in IMC causing inhibition of T cell responses (52). This phenomenon was
proposed to be mediated by integrins CD11b, CD18, and CD29 as pre-treating MDSC
with antibodies against these surface molecules abrogated the suppressive effect on the
lymphocytes. In addition to contributing to their suppressive function, ROS have also
been suggested to impede the differentiation of MDSC (127). MDSC with deleted
gp91phox gene, thus lacking NOX2 activity, did not demonstrate increased ROS level
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compared to IMC from naïve mice. Notably, lack of NOX2 activity blocked the
suppressive activity of MDSC on CD8+ T cells and allowed MDSC to differentiate into
mature myeloid cells in vitro. This strongly suggest that up-regulation of ROS in these
cells in cancer is controlled by NOX2 activity.
MDSC expansion in tumor-bearing hosts is mediated by various tumor-derived
factors (44). STAT3 is arguably one of the main transcription factors responsible for
MDSC accumulation in cancer. Signaling from many tumor-derived factors implicated in
MDSC expansion ultimately converge in the Jak/STAT3 pathway (162,163).
Consequently, MDSCs from tumor bearing mice have dramatically increased levels of
phosphorylated STAT3 compared to IMC from naive mice (50). Exposure of
hematopoietic progenitor cells to tumor-cell-conditioned medium resulted in the
activation of STAT3 and was associated with an expansion of MDSCs in vitro, whereas
inhibition of STAT3 in these cells abrogated the effect of tumor-derived factors on
MDSC expansion (51). Ablation of STAT3 using conditional-mutant mice or selective
inhibitors dramatically reduced the expansion of MDSCs and improved T-cell responses
in tumor-bearing mice (50, 161). Thus, it appears that abnormal persistent activation of
STAT3 in myeloid progenitors prevents differentiation of myeloid cells and is associated
with increased proliferation and survival of myeloid progenitors, possibly through upregulation of STAT3-targeted genes like Bcl-xL, cyclin D1, c-myc, survivin (162) or
S100A8 and S100A9 proteins (39). Due to such a prominent role of STAT3 in MDSC
biology, it was tempting to speculate that STAT3 could be responsible for enhanced
expression of NOX2. Our data suggests that STAT3 regulates expression of p47phox,
arguably one of the main components of the NOX2 complex, by directly binding to the
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p47phox gene promoter region. The experiments involving STAT3MT mice as well as overexpression of STAT3 in ES cells further corroborates to the role of STAT3 in
transcriptional regulation of p47phox and in addition suggest that gp91phox, the catalytic
subunit of NOX2, is controlled by STAT3 through a similar process. Regulation of ROS
in MDSC by STAT3 was further confirmed in experiments with JSI-124 (Fig. 7), a
selective STAT3 inhibitor (135). Overall, this provides a direct link between the various
tumor-derived factors affecting MDSC and the level of ROS in these cells.
Inside tumor tissues, the tumor microenvironment convert MDSC into potent
suppressor cells by up-regulating proteins involved in the metabolism of L-arginine.
These enzymes (iNOS and Arg I) are known to be actively involved in T-cell suppression
(164,165). Importantly, they do not require antigen-specific contact between MDSC and
T cells to inhibit their function. This last observation makes biological sense, as tumor
infiltrating lymphocytes are effector cells that have been activated in peripheral lymphoid
organs and thus have already produced cytotoxic granules. Recognition of antigen by
effector cells would lead to exocytosis of cytolytic enzymes (perforin and granzymes)
resulting in the destruction of the target cell, or in this particular case the elimination of
the MDSC. By circumventing the necessity of cell-to-cell interaction to activate their
suppressive function, MDSC can inhibit T cell activity through down-regulation of CD3! re-expression, blocking CTL degranulation, and inducing T cell apoptosis, all of which
are potential outcomes of iNOS and Arg 1 activity.
In order to make a fair comparison of the function of MDSC from spleen and
tumor sites, it was essential to ensure that we are indeed comparing cells with the same
phenotype. We sorted MDSC based on the expression of Gr-1 and CD11b, two markers
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that are considered hallmarks of MDSC. The expression of the macrophage cell marker
F4/80 was slightly higher on tumor MDSC than on spleen cells; however, this F4/80
expression was nowhere near the level expressed by TAMs. In addition, the MDSC we
isolated from the tumor site and spleen had similar morphology and expression of other
macrophage markers.
The difference in suppressive activity between MDSC from tumor and spleen was
quite substantial. While spleen MDSC contain a high level of ROS, and a relatively
modest level of NO and Arg I activity (although it was still elevated by comparison with
Gr-1+CD11b+ cells from naïve mice),

MDSC isolated from the tumor showed no

increase in ROS over naïve Gr-1+CD11b+ IMC but a very high level of NO and arginase
I. These biochemical disparities translated into fundamental differences in their ability to
suppress T cells. Tumor-MDSC were not only more potent inhibitors of antigen-specific
T-cell functions than spleen MDSC but also, in contrast to spleen MDSC, suppressed
non-specific

T

cells.

A

recent

study

found

that

in

spleens,

granulocytic

CD11b+Ly6G+Ly6Clow MDSC produce substantially higher level of ROS and a lower
level of NO than monocytic CD11b+Ly6G-Ly6Chigh cells (19). It was possible that the
composition of these MDSC subsets could be different in spleens and tumors which
would explain the differences in functional activity of MDSC. However, the populations
of MDSC in the spleen and tumor site contained similar ratios of granulocytic and
monocytic sub-populations. Furthermore, experiments involving the direct transfer of
spleen MDSC to the tumor microenvironment demonstrated that 4 hr was sufficient to
cause dramatic changes in MDSC activity. These experiments also indicate that the
observed differences were indeed specific for the relative MDSC population and not
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caused by possible contamination of macrophages since the phenotype of MDSC was not
changed within 4 hr after transfer (data not shown).
The upregulation of Arg1 and iNOS by MDSC in the tumor site is a very rapid
process and takes only hours to occur. One of the major factors that distinguish the tumor
microenvironment from lymphoid organs is hypoxia. Tumor hypoxia is of great clinical
concern as it can reduce the effectiveness of radiation therapy and lessen the efficacy of
cytotoxic drugs (166-168). It appears that hypoxia also plays a critical role in the
regulation of MDSC function by the tumor microenvironment. Our experiments have
demonstrated that exposure of spleen MDSC to hypoxia could reproduce the effect of the
tumor microenvironment on these cells by inducing a dramatic up-regulation of iNOS and
Arg 1, decreasing the expression of NOX2 and ROS, and shifting MDSC-suppression
from antigen-mediated to no requirement for antigen presentation.
The major molecular mechanism of the hypoxia effect is mediated by the HIF-1
transcription factor. In hematopoietic cells, HIF-1! is the predominant oxygen-sensitive
subunit (169). Regulation of HIF-1 activity is mediated by posttranslational modification
of the oxygen-dependent degradation domain (ODD) of HIF-1!. At oxygen levels above
5%, hydroxylation of the proline residues 402 and 564 in the ODD of HIF-1! enables
binding of the ubiquitination ligase von Hippel-Lindau tumor suppressor protein, which
leads to degradation of HIF-1! by the proteosome. In contrast, at oxygen levels below
5%, hydroxylation is inhibited leading to stabilization of HIF-1!. HIF-1! has been
directly implicated in the up-regulation of iNOS (170) and arginase (171,172) in
macrophages. HIF-1! has been shown to suppress oxidative phosphorylation and ROS
production in mitochondria (173,174).
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HIF-1! stabilization is not the only consequence of hypoxia exposure. One of the
outcomes resulting from the metabolic changes induced by hypoxia is the accumulation
of extracellular adenosine. Leukocytes express surface receptors capable of detecting
adenosine, a class of these adenosine receptors, A2aR and A2bR, has been associated
with immunosuppressive functions (175,176). The signaling cascade initiated through
these receptors results in increased concentrations of cAMP, leading to attenuation of
TCR-triggered T cell activation, TLR-triggered myeloid cell activation, and inhibition of
T cell proliferation and cytokine production (IFN-", TNF). Another outcome originating
due to tumor hypoxia is increased acidity in the tumor microenvironment. Under aerobic
conditions, the catabolism of glucose concludes in the oxidation of pyruvate to CO2 and
H2O in the mitochondria. However, in the situation when O2 is in short supply, glucose is
reduced to lactate, resulting in the production and accumulation of lactic acid in the
microenvironment of many cancer cell types (177). We investigated a potential role of
both of these factors, adenosine and acidity, in regulation of MDSC function. However,
neither treating MDSC with high adenosine concentrations nor lowering the pH in
medium of cell cultures, altered the suppressive activity of MDSC (data not shown).
These results, together with our data using mice reconstituted with a HIF-1!-deficient
leukocyte compartment, strongly argue that HIF-1! directly mediates the shift in
suppressive mechanisms employed by MDSC that was caused by the tumormicroenvironment.
MDSC have the potential to differentiate into macrophages and DCs (77,126),
and hypoxia, acting via HIF-1!, appears to have a direct effect on MDSC differentiation.
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Two days after our adoptive transfer experiment, more than 60% of MDSC that reached
the spleen retained an immature phenotype while the rest of the cells differentiated
evenly to macrop[hages and DCs. In contrast, MDSC transferred into tumor site
differentiated much more rapidly, with most of the cells acquiring the phenotype of
macrophages. In vitro culture of MDSC under hypoxic conditions recapitulated these
findings. Stabilization of HIF-1! with DFO reproduced this effect, suggesting that HIF1! could be an important factor regulating the differentiation of MDSC to TAM. MDSC
lacking HIF-1! did not differentiate into TAM within the tumor micoenvironemnt or
under in vitro hypoxia, but interestingly acquired markers of DCs instead. It has been
shown that in patients with cancer, tumors do contain small numbers of DCs. However,
the DCs present do not express co-stimulatory molecules or adequate levels of MHC
class II molecules and consequently are poor immune stimulators. For instance, it was
shown that renal-cell carcinomas or tumors of the prostate contain DCs that express
minimal levels of the costimulatory molecules CD80 and CD86 (178,179). Less than 1%
of DCs isolated from basal-cell carcinomas expressed either CD80 or CD86 (180), while
less than 10% of DCs isolated from colon carcinomas express CD80 or CD86. In the
absence of an appropriate co-stimulatory signal for T cells, together with the lack of
production of cytokines that are required for T-cell stimulation, any antigen presentation
by tumor infiltrating DCs might result in the induction of tolerance. In support of this
argument, DCs derived from colon-cancer tissue have been shown to be inducers of Tcell anergy (181). Thus, it will be interesting to further explore in detail the phenotype of
the DCs that differentiated from HIF-1! deficient MDSC inside the tumor; expression of
co-stimulatory molecules, of MHC proteins, and of cytokines must be evaluated, as well
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as their potential to induce an anti-tumor immune response.
Although we did not explore this thoroughly, our data with HIF-1!-deficient mice
indicate that this transcription factor may play an important role in MDSC expansion.
Expansion of MDSC from HIF-1!-deficient progenitors in tumor-bearing mice was
substantially lower than that from their HIF-1! wild-type counterparts. HIF-1! is
critically important during embryonic hematopoiesis. HIF-1! knockout mice develop
extensive hematopoietic pathologies and are embryonic lethal at day E10.5 due to neural
tube defects, dilated vasculature, and hyperplastic myocardium; absence of VEGF is
considered to be responsible for the defect. Involvement of HIF-1! in adult
hematopoiesis within the bone marrow has not yet been fully proven, but some reports
have pointed out the possible role of HIF-1! in myeloid cell differentiation.
Differentiation of the macrophage THP-1 cell line or monocytes from peripheral blood
caused up-regulation of HIF-1! and HIF-1", increasing HIF-1 transcriptional activity and
expression of HIF-1 target genes (182). Another study has shown that CD34+ and
CD133+ hematopoietic progenitor and stem cells express a stabilized cytoplasmic form of
HIF-1! even under normoxic conditions. HIF-1! stabilization is also positively
controlled by NADPH Oxidase-dependent production of ROS (183). In A549 cells,
hypoxic upregulation of NOX1 and the subsequently augmented ROS generation
activated HIF-1-dependent pathways (184). Furthermore, the upregulation of expression
of mRNA encoding HIF1! is induced by other stimuli, such as signaling mediated by
pro-inflammatory cytokines (185,186) insulin (187), thrombin, angiotensin II and
platelet-derived growth factor (188). Therefore, the possibility exists that up regulation of
HIF-1! target genes in myeloid progenitors may be mediated by ROS, tumor-secreted
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cytokines, or by other inflammatory mediators, partially contributing to the systemic
expansion of MDSC. Activation of HIF-1! by the aforementioned mechanisms in the
periphery may not be sufficient to drive the differentiation of MDSC into mature cells;
however, in the tumor, hypoxia likely induces multiple changes in MDSC, such as
possible regulation of transcription factors (unpublished observations), which in
combination with HIF-1! stabilization may promote differentiation to macrophages. It is
also possible that hypoxia potently activates HIF-1! to a much greater extent than
cytokines or inflammatory molecules can achieve, thus resulting in the activation of
different sets of genes in the two compartments.
Overall, this study may suggest a model of MDSC function and differentiation in
cancer. Tumor-derived factors, via constitutive up-regulation of STAT3 transcription
factors, induce an expansion of MDSC in BM of tumor-bearing hosts (39,50,130,189),
results in an accumulation of MDSC in peripheral lymphoid organs and in the tumor site.
In peripheral lymphoid organs, the accumulated MDSC contain high levels of NADPH
Oxidase components and any stimuli, including contact with surrounding cells, makes the
cells react with increased ROS productivity which contributes to the immunosuppressive
activity of these cells. Thus, NOX2 could be an attractive target in therapeutic regulation
of function of circulatory MDSC. In the tumor tissues, due to the effect of hypoxia via
HIF-1!, MDSC dramatically up-regulate expression of iNOS and ArgI, which is
associated with down-regulation of both NOX2 expression and ROS production. Because
of these changes, MDSC acquire the ability to suppress antigen non-specific T cell
functions, which contribute to the profound immune suppression observed within the
tumor microenvironment. In addition, hypoxia via HIF-1! promotes differentiation of
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MDSC to immune suppressive TAM that further support the immune suppressive
network (Fig.18). Elucidation of this dual role of MDSC may not only help to understand
the biology of tumor-associated immune suppression, but also suggest that any
therapeutic interventions should take into account the effect of spatial location on the
function of these cells.
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